Maria E. Cabanillas, M.D.

Peer-Reviewed Articles

1. Fournier I, Bandi AV, Hamidi S, Iyer P, Busaidy NL, Cabanillas ME, Dadu R, Hu MI, Waguespack SG, Basmaci UN, Williams MD, Mansour M, Monroe MG, Gross ND, Goepfert RP, Perrier ND, Banuchi V, Wang JR, Maniakas A, Zafereo ME. Management of Retropharyngeal Lymph Node Metastases in Thyroid Cancer. Head Neck 48(1):237-245, 2025. e-Pub 2025. PMID: 40891104.
2. Hawes EE, Banuchi VE, Maniakas A, Wang JR, Graham PH, Diersing JD, Busaidy NL, Cabanillas ME, Dadu R, Hamidi S, Iyer P, Waguespack SG, Ahmed S, Alizada S, Belcastro A, Alsharif R, Hu MI, Zafereo ME. Partial Laryngectomy for Thyroid Cancer: A Single Institution Case Series With Operative Techniques. Head Neck 48(2):E20-E24, 2025. e-Pub 2025. PMID: 40747656.
3. Cabanillas ME, Busaidy NL, Gunn GB, Iyer PC, Ferrarotto R, Gule-Monroe M, Maniakas A, Williams MD, Liu S, Fellman B, Spiotto M, Hamidi S, Akhave N, Lee A, Wang JR, de Sousa L, Marczyk VR, Zafereo M, Dadu R. Adjuvant Pembrolizumab after Upfront Multimodal Therapy for Stage IVB Anaplastic Thyroid Cancer. Thyroid 35(7):763-770, 2025. e-Pub 2025. PMID: 40609521.
4. Hamidi S, Maniakas A, Akhave NS, Banuchi VE, Busaidy NL, Dadu R, Ferrarotto R, Guise TA, Hofmann MC, Hosseini SM, Hu MI, Iyer PC, Mansour M, Marczyk VR, Roy-Chowdhuri S, Sherman SI, Sousa LG, Wang JR, Williams MD, Zafereo ME, Waguespack SG, Cabanillas ME. Characterization of advanced RAS-driven follicular-derived thyroid cancers and review of future therapeutic avenues. J Clin Endocrinol Metab, 2025. e-Pub 2025. PMID: 40568752.
5. Hamidi S, Dadu R, Iyer PC, Busaidy NL, Maniakas A, Wang JR, Banuchi VE, Hosseini SM, Williams MD, Zafereo ME, Cabanillas ME. Circulating Tumor DNA as a Biomarker for Disease Surveillance in Anaplastic Thyroid Cancer. JCO Precis Oncol 9:e2500067, 2025. e-Pub 2025. PMID: 40570261.
6. Houl JH, Bagheri-Yarmand R, Kunnimalaiyaan M, Miranda Mendez P, Kidd JL, Dadbin A, Jurado Ruiz A, Parekh PA, Henderson YC, Chari NS, Thennavan AT, Powell RT, Stephan CC, Zhao X, Maniakas A, Nurieva R, Busaidy NL, Cabanillas ME, Dadu R, Zafereo M, Wang JR, Lai SY, Hofmann MC. Role of the ETV5/p38 signaling axis in aggressive thyroid cancer cells. bioRxiv, 2025. e-Pub 2025. PMID: 40027641.
7. Wang JR, Zafereo ME, Cabanillas ME, Wu CC, Xu L, Dai Y, Wang W, Lai SY, Henderson Y, Erasmus L, Williams MD, Joshu C, Ray D. The Association Between Thyroid Differentiation Score and Survival Outcomes in Papillary Thyroid Carcinoma. J Clin Endocrinol Metab 110(2):356-363, 2025. e-Pub 2025. PMID: 39087944.
8. Marczyk, VR, Fazeli, S, Dadu, R, Busaidy, NL, Iyer, PC, Hu, MI, Sherman, SI, Hamidi, S, Hosseini, SM, Williams, MD, Ahmed, S, Routbort, MJ, Luthra, R, Roy Chowdhuri, S, San Lucas, FA, Patel, KP, Hong, DS, Zafereo, M, Wang, RJ, Maniakas, A, Waguespack, SG, Cabanillas, ME. NTRK Fusion-Positive Thyroid Carcinoma. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 39983078.
9. Dudzinski, SO, Cabanillas, ME, Hamidi, S, Marczyk, VR, Busaidy, NL, Dadu, R, Welsh, J, Hu, MI, Gunn, GB, Wang, C, Waguespack, SG, Phan, J, Beckham, TH, Chang, JY, Sherman, SI, Reddy, JP, Ying, AK, O'Reilly, M, Chen, A, Lee, A, Gandhi, S, Liao, Z, Ludmir, EB, Nguyen, Q, Lin, SH, Zafereo, M, Ning, M. Definitive Radiotherapy for Oligometastatic and Oligoprogressive Thyroid Cancer. JNCCN Journal of the National Comprehensive Cancer Network 23(1), 2025. e-Pub 2025. PMID: 39662038.
10. Cabanillas ME, MD. Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. npj Precision Oncology 8(1), 2024. e-Pub 2024. PMID: 38438731.
11. Dagher SA, Learned KO, Dagher R, Wang JR, Zhao X, Hosseini SM, Maniakas A, Cabanillas ME, Busaidy NL, Dadu R, Iyer P, Zafereo ME, Khalaf AM. [18F]-Fluorodeoxyglucose Uptake as a Marker of Residual Anaplastic and Poorly Differentiated Thyroid Carcinoma Following BRAF-Targeted Therapy. AJNR Am J Neuroradiol 46(6):1260-1267, 2024. e-Pub 2024. PMID: 39572200.
12. Bronk JK, Augustyn A, Mohamed ASR, David Fuller C, Garden AS, Moreno AC, Lee A, Morrison WH, Phan J, Reddy JP, Rosenthal DI, Spiotto MT, Frank SJ, Dadu R, Busaidy N, Zafereo M, Wang JR, Maniakas A, Ferrarotto R, Iyer PC, Cabanillas ME, Gunn GB. Patterns of loco-regional progression and patient outcomes after definitive-dose radiation therapy for anaplastic thyroid cancer. Radiother Oncol 202:110602, 2024. e-Pub 2024. PMID: 39489425.
13. Cabanillas ME, Dadu R, Ferrarotto R, Gule-Monroe M, Liu S, Fellman B, Williams MD, Zafereo M, Wang JR, Lu C, Ning M, McKinley BA, Woodman SE, Duose D, Gunn GB, Busaidy NL. Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. JAMA Oncol 10(12):1672-1680, 2024. e-Pub 2024. PMID: 39446377.
14. Hamidi S, Dadu R, Zafereo ME, Ferrarotto R, Wang JR, Maniakas A, Gunn GB, Lee A, Spiotto MT, Iyer PC, Sousa LG, Akhave NS, Ahmed S, Learned KO, Lu C, Lai SY, Williams M, Hosseini SM, Busaidy NL, Cabanillas ME. Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement. JAMA Oncol 10(9):1264-1271, 2024. e-Pub 2024. PMID: 38990526.
15. Iyer PC, Dadu R, Cabanillas ME. Analytical Validation of a Telomerase Reverse Transcriptase (TERT) Promoter Mutation Assay. J Clin Endocrinol Metab 109(9):2269-2273, 2024. e-Pub 2024. PMID: 38441247.
16. Awad A, Pal K, Maniakas A, Zafereo M, Grosu H, Cabanillas M, Chen SR. Carotid blowout into the trachea: unusual entity with unexpected management outcome. J Neurointerv Surg 16(7):743-746, 2024. e-Pub 2024. PMID: 37532452.
17. Shirali AS, Hu MI, Chiang YJ, Graham PH, Fisher SB, Sosa JA, Perrier N, Brown S, Holla VR, Dadu R, Busaidy N, Sherman SI, Cabanillas M, Waguespack SG, Zafereo ME, Grubbs EG. Next-Generation Sequencing in Sporadic Medullary Thyroid Cancer Patients: Mutation Profile and Disease Aggressiveness. J Endocr Soc 8(6):bvae048, 2024. e-Pub 2024. PMID: 38660141.
18. Sarvestani AL, Lambdin J, Hu M, Cabanillas M, Waguespack SG, Hernandez JM, Zafereo ME. Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancers. Ann Surg Oncol 31(4):2202-2203, 2024. e-Pub 2024. PMID: 38245643.
19. Nelson BE, Roszik J, Ahmed J, Barretto CMN, Nardo M, Campbell E, Johnson AM, Piha-Paul SA, Oliva ICG, Weathers SP, Cabanillas M, Javle M, Meric-Bernstam F, Subbiah V. RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study. Mol Cancer 23(1):64, 2024. e-Pub 2024. PMID: 38532456.
20. Hawes EE, Cabanillas ME, Hutcheson K, Barbon C, Dadu R, Busaidy NL, Iyer PC, Siddiqui SH, Maniakas A, Wang JR, E Zafereo AM. Recurrent Laryngeal Nerve Recovery After Neoadjuvant Therapy for BRAF-Mutated Anaplastic Thyroid Cancer. VideoEndocrinology™ 11(1), 2024. e-Pub 2024.
21. Hamidi S, Iyer P, Dadu R, Gule-Monroe M, Maniakas A, Zafereo ME, Wang JR, Busaidy N, Cabanillas M. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E Mutated Anaplastic Thyroid Carcinoma. Thyroid, 2024. e-Pub 2024. PMID: 38226606.
22. Maniakas A, Sullivan A, Hu MI, Busaidy NL, Cabanillas ME, Dadu R, Waguespack SG, Fisher SB, Graham PH, Gross ND, Grubbs EG, Perrier ND, Wang JR, Gunn B, Garden AS, Megahed R, Navuluri S, Li X, Williams MD, Zafereo M. Decreasing utilization for postoperative radiation therapy in locoregionally advanced medullary thyroid cancer. Head Neck 46(2):328-335, 2024. e-Pub 2024. PMID: 38009416.
23. Silver Karcioglu A, Abdelhamid Ahmed AH, Feng Z, Russell M, Shonka DC, Iwata A, Cabanillas M, Shin JJ, Kyriazidis N, Park JC, Wirth LJ, Zafereo ME, Randolph GW. Return of Vocal Fold Motion and Surgical Preservation of Invaded Recurrent Laryngeal Nerves After the Use of Neoadjuvant Therapy in Patients Presenting with Advanced Thyroid Cancer and Vocal Fold Paralysis: The Lazarus Effect. Thyroid 33(10):1259-1263, 2023. e-Pub 2023. PMID: 37694677.
24. Lu L, Wang JR, Henderson YC, Bai S, Yang J, Hu M, Shiau CK, Pan T, Yan Y, Tran TM, Li J, Kieser R, Zhao X, Wang J, Nurieva R, Williams MD, Cabanillas ME, Dadu R, Busaidy NL, Zafereo M, Navin N, Lai SY, Gao R. Anaplastic transformation in thyroid cancer revealed by single cell transcriptomics. J Clin Invest 133(11), 2023. e-Pub 2023. PMID: 37053016.
25. Zhao X, Wang JR, Dadu R, Busaidy NL, Xu L, Learned KO, Chasen NN, Vu T, Maniakas A, Eguia AA, Diersing J, Gross ND, Goepfert R, Lai SY, Hofmann MC, Ferrarotto R, Lu C, Gunn GB, Spiotto MT, Subbiah V, Williams MD, Cabanillas ME, Zafereo ME. Surgery after BRAF-directed therapy is associated with improved survival in BRAF V600E mutant Anaplastic Thyroid Cancer. Thyroid 33(4):484-491, 2023. e-Pub 2023. PMID: 36762947.
26. Shenson JA, Zafereo ME, Lee M, Contrera KJ, Feng L, Boonsripitayanon M, Gross N, Goepfert R, Maniakas A, Wang JR, Grubbs L, Vaporciyan A, Hofstetter W, Swisher S, Mehran R, Rice D, Sepesi B, Antonoff M, Cabanillas M, Busaidy N, Dadu R, Silver NL. Clinical outcomes of combined cervical and transthoracic surgical approaches in patients with advanced thyroid cancer. Head Neck 45(3):547-554, 2023. e-Pub 2023. PMID: 36524701.
27. Chen YH, Cabanillas M, Sperling J, Xu L, Goswami M, Maniakas A, Williams MD, Lai SY, Busaidy N, Dadu R, Zafereo ME, Wang JR. Prior thyroid and non-thyroid cancer history do not significantly alter overall survival in patients diagnosed with anaplastic thyroid carcinoma. Thyroid 33(3):321-329, 2023. e-Pub 2023. PMID: 36511380.
28. Nelson BE, Roszik J, Janku F, Hong DS, Kato S, Naing A, Piha-Paul S, Fu S, Tsimberidou A, Cabanillas M, Busaidy NL, Javle M, Byers LA, Heymach JV, Meric-Bernstam F, Subbiah V. BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study. NPJ Precis Oncol 7(1):19, 2023. e-Pub 2023. PMID: 36801912.
29. Contrera KJ, Gule-Monroe MK, Hu MI, Cabanillas ME, Busaidy NL, Dadu R, Waguespack SG, Wang JR, Maniakas A, Lai SY, Diersing J, Kwon M, Grubbs EG, Subbiah V, Williams MD, Zafereo ME. Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series. Thyroid 33(1):129-132, 2023. e-Pub 2023. PMID: 36503246.
30. Busaidy NL, Konda B, Wei L, Wirth LJ, Devine C, Daniels GA, DeSouza JA, Poi M, Seligson ND, Cabanillas ME, Sipos JA, Ringel MD, Eisfeld AK, Timmers C, Shah MH. Dabrafenib vs dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer - results of a randomized, phase 2, open-label, multicenter trial. Thyroid 32(10):1184-1192, 2022. e-Pub 2022. PMID: 35658604.
31. Wang JR, Montierth M, Xu L, Goswami M, Zhao X, Cote G, Wang W, Iyer P, Dadu R, Busaidy NL, Lai SY, Gross ND, Ferrarotto R, Lu C, Gunn GB, Williams MD, Routbort M, Zafereo ME, Cabanillas ME. Impact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid Carcinoma. JCO Precis Oncol 6:e2100504, 2022. e-Pub 2022. PMID: 35977347.
32. Shonka DC, Ho A, Chintakuntlawar AV, Geiger JL, Park JC, Seetharamu N, Jasim S, Abdelhamid Ahmed AH, Bible KC, Brose MS, Cabanillas ME, Dabekaussen K, Davies L, Dias-Santagata D, Fagin JA, Faquin WC, Ghossein RA, Gopal RK, Miyauchi A, Nikiforov YE, Ringel MD, Robinson B, Ryder MM, Sherman EJ, Sadow PM, Shin JJ, Stack BC, Tuttle RM, Wirth LJ, Zafereo ME, Randolph GW. American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group Consensus Statement on Mutational Testing in Thyroid Cancer: Defining Advanced Thyroid Cancer and its Targeted Treatment. Head Neck 44(6):1277-1300, 2022. e-Pub 2022. PMID: 35274388.
33. Waguespack SG, Drilon A, Lin JJ, Brose MS, McDermott R, Almubarak M, Bauman J, Casanova M, Krishnamurthy A, Kummar S, Leyvraz S, Oh DY, Park K, Sohal D, Sherman E, Norenberg R, Silvertown JD, Brega N, Hong DS, Cabanillas ME. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endocrinol 186(6):631-643, 2022. e-Pub 2022. PMID: 35333737.
34. Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski CC, Cabanillas ME, Boran A, Ilankumaran P, Burgess P, Romero Salas T, Keam B. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol 33(4):406-415, 2022. e-Pub 2022. PMID: 35026411.
35. Vander Poorten V, Goedseels N, Triantafyllou A, Sanabria A, Clement PM, Cohen O, Golusinski P, Guntinas-Lichius O, Piazza C, Randolph GW, Rinaldo A, Ronen O, Cabanillas ME, Shaha AR, Teng Y, Tufano RP, Williams MD, Zafereo M, Ferlito A. Effectiveness of core needle biopsy in the diagnosis of thyroid lymphoma and anaplastic thyroid carcinoma: A systematic review and meta-analysis. Front Endocrinol (Lausanne) 13:971249, 2022. e-Pub 2022. PMID: 36204100.
36. Maniakas A, Henderson YC, Hei H, Peng S, Chen Y, Jiang Y, Ji S, Cardenas M, Chiu Y, Bell D, Williams MD, Hofmann MC, Scherer SE, Wheeler DA, Busaidy NL, Dadu R, Wang JR, Cabanillas ME, Zafereo M, Johnson FM, Lai SY. Novel anaplastic thyroid cancer PDXs and cell lines: Expanding preclinical models of genetic diversity. J Clin Endocrinol Metab 106(11):e4652-e4665, 2021. e-Pub 2021. PMID: 34147031.
37. Bagheri-Yarmand R, Busaidy NL, McBeath E, Danysh BP, Evans KW, Moss TJ, Akcakanat A, Ng PKS, Knippler CM, Golden JA, Williams MD, Multani AS, Cabanillas ME, Shaw KR, Meric-Bernstam F, Shah MH, Ringel MD, Hofmann MC. RAC1 Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient. Cancers (Basel) 13(19), 2021. e-Pub 2021. PMID: 34638434.
38. Henderson YC, Mohamed ASR, Maniakas A, Chen Y, Powell RT, Peng S, Cardenas M, Williams MD, Bell D, Zafereo ME, Wang RJ, Scherer SE, Wheeler DA, Cabanillas ME, Hofmann MC, Johnson FM, Stephan CC, Sandulache V, Lai SY. A High-Throughput Approach to Identify Effective Systemic Agents for the Treatment of Anaplastic Thyroid Carcinoma. J Clin Endocrinol Metab 106(10):2962-2978, 2021. e-Pub 2021. PMID: 34120183.
39. Patel RR, He K, Barsoumian HB, Chang JY, Tang C, Verma V, Comeaux N, Chun SG, Gandhi S, Truong MT, Erasmus JJ, Hong DS, Lee PP, Ning MS, Nguyen QN, Heymach JV, Altan M, Blumenschein G, Fossella FV, Sezen D, Chen D, Carter BW, Davies MA, Glitza IC, Diab A, Ferrarotto R, Cabanillas ME, Yuan Y, Shah SJ, Parra ER, Sun B, Cortez MA, Welsh JW. High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: results of a phase II trial. Radiother Oncol 162:60-67, 2021. e-Pub 2021. PMID: 34237343.
40. Qin Y, Wang JR, Wang Y, Iyer P, Cote GJ, Busaidy NL, Dadu R, Zafereo M, Williams MD, Ferrarotto R, Gunn GB, Wei P, Patel K, Hofmann MC, Cabanillas ME. Clinical Utility of Circulating Cell-free DNA Mutations in Anaplastic Thyroid Carcinoma. Thyroid 31(8):1235-1243, 2021. e-Pub 2021. PMID: 33599171.
41. Wirth LJ, Brose MS, Sherman EJ, Licitra L, Schlumberger M, Sherman SI, Bible KC, Robinson B, Rodien P, Godbert Y, De La Fouchardiere C, Newbold K, Nutting C, Misir S, Xie R, Almonte A, Ye W, Cabanillas ME. Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer. J Clin Oncol 39(21):JCO2003093, 2021. e-Pub 2021. PMID: 33961488.
42. Shojaie D, Hoffman AS, Amaku R, Cabanillas ME, Sosa JA, Waguespack SG, Zafereo ME, Hu MI, Grubbs EE. Decision Making When Cancer Becomes Chronic: Needs Assessment for a Web-Based Medullary Thyroid Carcinoma Patient Decision Aid. JMIR Form Res 5(7):e27484, 2021. e-Pub 2021. PMID: 34269691.
43. Nguyen H, Shah K, Waguespack SG, Hu MI, Habra MA, Cabanillas ME, Busaidy NL, Bassett R, Zhou S, Iyer PC, Simmons G, Kaya D, Pitteloud M, Subudhi SK, Diab A, Dadu R. Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns. Endocr Relat Cancer 28(7):419-431, 2021. e-Pub 2021. PMID: 33890870.
44. Nies M, Vassilopoulou-Sellin R, Bassett RL, Yedururi S, Zafereo ME, Cabanillas ME, Sherman SI, Links TP, Waguespack SG. Distant metastases from childhood differentiated thyroid carcinoma: clinical course and mutational landscape. J Clin Endocrinol Metab 106(4):e1683-e1697, 2021. e-Pub 2021. PMID: 33382403.
45. Subbiah V, Shen T, Terzyan SS, Liu X, Hu X, Patel KP, Hu M, Cabanillas M, Behrang A, Meric-Bernstam F, Vo PTT, Mooers BHM, Wu J. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann Oncol 32(2):261-268, 2021. e-Pub 2021. PMID: 33161056.
46. Jozaghi Y, Zafereo M, Williams MD, Gule-Monroe MK, Wang J, Grubbs EG, Vaporciyan A, Hu MI, Busaidy N, Dadu R, Waguespack SG, Subbiah V, Cabanillas M. Neoadjuvant Selpercatinib for Advanced Medullary Thyroid Cancer. Head Neck 43(1):E7-E12, 2021. e-Pub 2021. PMID: 33169506.
47. Datar S, Cabanillas M, Dadu R, Ost D, Grosu HB. Pulmonary cavitation in patients with thyroid cancer receiving antiangiogenic agents. BMC Cancer 20(1):1181, 2020. e-Pub 2020. PMID: 33267782.
48. Hegde A, Andreev-Drakhlin AY, Roszik J, Huang L, Liu S, Hess K, Cabanillas M, Hu MI, Busaidy NL, Sherman SI, Dadu R, Grubbs EG, Ali SM, Lee J, Elamin YY, Simon GR, Blumenschein GR, Papadimitrakopoulou VA, Hong D, Meric-Bernstam F, Heymach J, Subbiah V. Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. ESMO Open 5(5):e000799, 2020. e-Pub 2020. PMID: 33097651.
49. Maniakas A, Dadu R, Busaidy NL, Wang JR, Ferrarotto R, Lu C, Williams MD, Gunn GB, Hofmann MC, Cote G, Sperling J, Gross ND, Sturgis EM, Goepfert RP, Lai SY, Cabanillas ME, Zafereo M. Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019. JAMA Oncol 6(9):1397-1404, 2020. e-Pub 2020. PMID: 32761153.
50. Cabanillas ME, Dadu R, Iyer P, Wanland KB, Busaidy NL, Ying A, Gule-Monroe M, Wang JR, Zafereo M, Hofmann MC. Acquired Secondary RAS Mutation in BRAFV600E Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors. Thyroid 30(9):1288-1296, 2020. e-Pub 2020. PMID: 32216548.
51. Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, Worden F, Brose M, Patel J, Leboulleux S, Godbert Y, Barlesi F, Morris JC, Owonikoko TK, Tan DSW, Gautschi O, Weiss J, de la Fouchardière C, Burkard ME, Laskin J, Taylor MH, Kroiss M, Medioni J, Goldman JW, Bauer TM, Levy B, Zhu VW, Lakhani N, Moreno V, Ebata K, Nguyen M, Heirich D, Zhu EY, Huang X, Yang L, Kherani J, Rothenberg SM, Drilon A, Subbiah V, Shah MH, Cabanillas ME. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med 383(9):825-835, 2020. e-Pub 2020. PMID: 32846061.
52. Jozaghi Y, Zafereo ME, Perrier ND, Wang JR, Grubbs E, Gross ND, Fisher S, Sturgis EM, Goepfert RP, Lai SY, Best C, Busaidy NL, Cabanillas ME, Dadu R, Gagel RF, Habra MA, Hu MI, Jimenez C, Sherman SI, Thosani S, Varghese J, Waguespack SG, Weitzman S, Ying AK, Graham PH. Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage Guidelines. Head Neck 42(6):1325-1328, 2020. e-Pub 2020. PMID: 32437031.
53. Debnam JM, Guha-Thakurta N, Sun J, Wei W, Zafereo ME, Cabanillas ME, Buisson NM, Schellingerhout D. Distinguishing Recurrent Thyroid Cancer from Residual Nonmalignant Thyroid Tissue Using Multiphasic Multi-detector Computed Tomography. AJNR Am J Neuroradiol 41(5):844-851, 2020. e-Pub 2020. PMID: 32327435.
54. Saltijeral SN, Cabanillas M, Kleiman A, Grosu HB. An unusual cause of respiratory failure. Journal of Clinical and Translational Endocrinology 17, 2020. e-Pub 2020.
55. Boyce-Fappiano D, Gjyshi O, Pezzi TA, Allen PK, Solimman M, Taku N, Bernstein MB, Cabanillas ME, Amini B, Tatsui CE, Rhines LD, Wang XA, Briere TM, Yeboa DN, Bishop AJ, Li J, Ghia AJ. Spine Stereotactic Radiosurgery for Metastatic Thyroid Cancer: A Single Institution Experience. J Neurosurg Spine:1-9, 2020. e-Pub 2020. PMID: 32059183.
56. Maxwell JE, Gule-Monroe MK, Subbiah V, Hu M, Perrier ND, Cabanillas ME, Lee JE, Graham PH, Cote GJ, Busaidy NL, Grubbs EG. Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in sporadic medullary thyroid carcinoma. Surgery 167(1):80-86, 2020. e-Pub 2020. PMID: 31648931.
57. Andreev-Drakhlin A, Cabanillas M, Amini B, Subbiah V. Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases. JCO Precis Oncol 4, 2020. e-Pub 2020. PMID: 33154983.
58. Welsh JW, Tang C, de Groot P, Naing A, Hess KR, Heymach JV, Papadimitrakopoulou VA, Cushman TR, Subbiah V, Chang JY, Simon GR, Ramapriyan R, Barsoumian HB, Menon H, Cortez MA, Massarelli E, Nguyen Q, Sharma P, Allison JP, Diab A, Verma V, Raju U, Shaaban SG, Dadu R, Cabanillas ME, Wang K, Anderson C, Gomez DR, Hahn S, Komaki R, Hong DS. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res 7(12):1903-1909, 2019. e-Pub 2019. PMID: 31658994.
59. Tetzlaff MT, Tang S, Duke T, Grabell DA, Cabanillas ME, Zuo Z, Yao JC, Nagarajan P, Aung PP, Torres-Cabala CA, Duvic M, Prieto VG, Huen A, Curry JL. Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis-fungoides–like morphologic and molecular. J Cutan Pathol 46(11):872-877, 2019. e-Pub 2019. PMID: 31254410.
60. Kutahyalioglu M, Nguyen HT, Kwatampora L, Clarke C, Silva A, Ibrahim E, Waguespack SG, Cabanillas ME, Jimenez C, Hu MI, Sherman SI, Kopetz S, Broaddus R, Dadu R, Wanland K, Williams M, Zafereo M, Perrier N, Busaidy NL. Genetic profiling as a clinical tool in advanced parathyroid carcinoma. J Cancer Res Clin Oncol 145(8):1977-1986, 2019. e-Pub 2019. PMID: 31309300.
61. Wang JR, Zafereo ME, Dadu R, Ferrarotto R, Busaidy NL, Lu C, Ahmed S, Gule-Monroe MK, Williams MD, Sturgis EM, Goepfert RP, Gross ND, Lai SY, Gunn GB, Phan J, Rosenthal DI, Fuller CD, Morrison WH, Iyer P, Cabanillas ME. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAFV600E-mutated anaplastic thyroid carcinoma. Thyroid 29(8):1036-1043, 2019. e-Pub 2019. PMID: 31319771.
62. Khan SA, Ci B, Xie Y, Gerber DE, Beg MS, Sherman SI, Cabanillas ME, Busaidy NL, Burtness BA, Heilmann AM, Bailey M, Ross JS, Sher DJ, Ali SM. Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling. Head Neck 41(6):1928-1934, 2019. e-Pub 2019. PMID: 30758123.
63. Ye W, Hannigan B, Zalles S, Mehrotra M, Barkoh BA, Williams MD, Cabanillas ME, Edeiken-Monroe B, Hu P, Duose D, Wistuba II, Medeiros LJ, Stewart J, Luthra R, Roy-Chowdhuri S. Centrifuged Supernatants from Fine Needle Aspiration Provide a Liquid Biopsy Option for Clinical Next-Generation Sequencing of Thyroid Nodules. Cancer Cytopathol 127(3):146-160, 2019. e-Pub 2019. PMID: 30620446.
64. Sagiv O, Kandl TJ, Thakar SD, Thuro BA, Busaidy NL, Cabanillas M, Jimenez C, Dadu R, Graham PH, Debnam JM, Esmaeli B. Extraocular Muscle Enlargement and Thyroid Eye Disease-like Orbital Inflammation Associated with Immune Checkpoint Inhibitor Therapy in Cancer Patients. Ophthalmic Plast Reconstr Surg 35(1):50-52, 2019. e-Pub 2019. PMID: 29927883.
65. Kazzaz FI, Cabanillas ME, Bashoura L, Shannon VR, Faiz SA. Bilateral spontaneous pneumothoraces in anaplastic thyroid cancer. Respir Med Case Rep 26:197-199, 2019. e-Pub 2019. PMID: 30705818.
66. Angell TE, Wirth LJ, Cabanillas ME, Shindo ML, Cibas ES, Babiarz JE, Hao Y, Kim SY, Walsh PS, Huang J, Kloos RT, Kennedy GC, Waguespack SG. Analytical and Clinical Validation of Expressed Variants and Fusions from the Whole Transcriptome of Thyroid FNA Samples. Front Endocrinol (Lausanne) 10:612, 2019. e-Pub 2019. PMID: 31572297.
67. Iyer PC, Cote GJ, Hai T, Gule-Monroe M, Bui-Griffith J, Williams MD, Hess K, Hofmann MC, Dadu R, Zafereo M, Busaidy NL, Ferrarotto R, Subbiah V, Gross N, Gunn BJ, Garden AS, Skinner HD, Cabanillas ME. Circulating BRAF V600E cell free DNA (cfDNA) as a biomarker in the management of Anaplastic Thyroid Carcinoma. JCO Precision Oncology 2:1-11, 2018. e-Pub 2018.
68. Puli O, Danysh BP, Sinha DK, Hoang NM, Rowell R, Danysh H, Cabanillas ME, Cote GJ, Hofmann M. The transcription factor ETV5 mediates BRAFV600E-induced proliferation and TWIST1 expression in papillary thyroid cancer cells. Neoplasia, 2018. e-Pub 2018.
69. Amit M, Boonsripitayanon M, Goepfert RP, Tam S, Busaidy NL, Cabanillas ME, Dadu R, Varghese J, Waguespack SG, Gross ND, Graham P, Williams MD, Sturgis EM, Zafereo ME. Extrathyroidal Extension: Does Strap Muscle Invasion Alone Influence Recurrence and Survival in Patients with Differentiated Thyroid Cancer?. Ann Surg Oncol, 2018. e-Pub 2018. PMID: 30022274.
70. Iyer PC, Cabanillas M, Waguespack SG, Hu MI, Thosani SN, Lavis VR, Busaidy N, Subudhi SK, Diab A, Dadu R. Immune-Related Thyroiditis with Immune Checkpoint Inhibitors. Thyroid, 2018. e-Pub 2018. PMID: 30132401.
71. Boonsripitayanon M, Tam S, Amit M, Busaidy NL, Cabanillas ME, Dadu R, Sherman S, Waguespack SG, Williams MD, Goepfert R, Gross ND, Sturgis EM, Perrier N, Zafereo ME. Survival in Differentiated Thyroid Cancer: Comparing the AJCC Cancer Staging 7th and 8th editions. Thyroid, 2018. e-Pub 2018. PMID: 30141373.
72. Jaber T, Waguespack SG, Cabanillas ME, Elbanan M, Vu T, Dadu R, Sherman SI, Amit M, Santos EB, Zafereo M, Busaidy NL. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine. J Clin Endocrinol Metab, 2018. e-Pub 2018.
73. Subbiah V, Velcheti V, Tuch BB, Ebata K, Busaidy NL, Cabanillas ME, Wirth LJ, Stock S, Smith S, Lauriault V, Corsi-Travali S, Henry D, Burkard M, Hamor R, Bouhana K, Winski S, Wallace RD, Hartley D, Rhodes S, Reddy M, Brandhuber BJ, Andrews S, Rothenberg SM, Drilon A. Selective RET Kinase Inhibition for Patients with RET-Altered Cancers. Ann Oncol 29(8):1869-1876, 2018. e-Pub 2018. PMID: 29912274.
74. Tam S, Amit M, Boonsripitayanon M, Busaidy NL, Cabanillas ME, Waguespack SG, Gross ND, Grubbs EG, Williams MD, Lai SY, Sturgis EM, Zafereo ME. Effect of Tumor Size and Minimal Extrathyroidal Extension in Patients with Differentiated Thyroid Cancer. Thyroid 28(8):982-990, 2018. e-Pub 2018. PMID: 29936892.
75. Chavez AAL, Iyer P, Cazacu IM, Cabanillas ME, Rashid A, Bhutani MS. Anaplastic Thyroid Carcinoma with Gastric Metastasis. Curr Health Sci J 44(3):294-298, 2018. e-Pub 2018. PMID: 30647951.
76. Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, Zafereo M, Williams MD, Gunn GB, Grosu H, Skinner HD, Sturgis EM, Gross N, Cabanillas ME. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer, 2018. e-Pub 2018.
77. Chen H, Luthra R, Routbort MJ, Patel KP, Cabanillas ME, Broaddus RR, Williams MD. Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing tumors beyond diagnosis for targeted therapy. Mol Cancer Ther 17(7):1575-1584, 2018. e-Pub 2018. PMID: 29695638.
78. Cabanillas ME, Ferrarotto R, Garden AS, Ahmed S, Busaidy NL, Dadu R, Williams MD, Skinner H, Gunn GB, Grosu H, Iyer P, Hofmann MC, Zafereo M. Neoadjuvant BRAF- and immune- directed therapy for anaplastic thyroid carcinoma. Thyroid 28(7):945-951, 2018. e-Pub 2018. PMID: 29742974.
79. Smith AL, Williams MD, Stewart J, Wang WL, Krishnamurthy S, Cabanillas ME, Roy-Chowdhuri S. Utility of the BRAF p.V600E immunoperoxidase stain in FNA direct smears and cell block preparations from patients with thyroid carcinoma. Cancer Cytopathol 126(6):406-413, 2018. e-Pub 2018. PMID: 29579361.
80. Hanna GJ, Busaidy NL, Chau NG, Wirth LJ, Barletta JA, Calles A, Haddad RI, Kraft S, Cabanillas ME, Rabinowits G, O'Neill A, Limaye SA, Alexander EK, Moore FD, Misiwkeiwicz K, Thomas T, Nehs M, Marqusee E, Lee SL, Jänne PA, Lorch JH. Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study. Clin Cancer Res 24(7):1546-1553, 2018. e-Pub 2018. PMID: 29301825.
81. Ahmed S, Ghazarian MP, Cabanillas ME, Zafereo ME, Williams MD, Vu T, Schomer DF, Debnam JM. Imaging of Anaplastic Thyroid Carcinoma. AJNR Am J Neuroradiol 39(3):547-551, 2018. e-Pub 2018. PMID: 29242360.
82. Sakamuri D, Glitza IC, Betancourt Cuellar SL, Subbiah V, Fu S, Tsimberidou AM, Wheler JJ, Hong DS, Naing A, Falchook GS, Fanale MA, Cabanillas ME, Janku F. Phase 1 dose-escalation study of anti CTLA-4 antibody ipilimumab and lenalidomide in patients with advanced cancers. Mol Cancer Ther 17(3):671-676, 2018. e-Pub 2018. PMID: 29237802.
83. Amit M, Tam S, Boonsripitayanon M, Cabanillas ME, Busaidy NL, Grubbs EG, Lai SY, Gross ND, Sturgis EM, Zafereo ME. Association of Lymph Node Density With Survival of Patients With Papillary Thyroid Cancer. JAMA Otolaryngol Head Neck Surg 144(2):108-114, 2018. e-Pub 2018. PMID: 29192312.
84. Pena I, Clayman GL, Grubbs EG, Bergeron JM, Waguespack SG, Cabanillas ME, Dadu R, Hu MI, Fellman BM, Li Y, Gross ND, Lai SY, Sturgis EM, Zafereo ME. Management of the Lateral Neck Compartment in Patients with Sporadic Medullary Thyroid Cancer. Head Neck 40(1):79-85, 2018. e-Pub 2018. PMID: 29044788.
85. Iyer PC, Dadu R, Ferrarotto R, Busaidy NL, Habra MA, Zafereo M, Gross N, Hess KR, Gule-Monroe M, Williams MD, Cabanillas ME. Real world experience with targeted therapy for the treatment of anaplastic thyroid carcinoma. Thyroid 28(1):79-87, 2018. e-Pub 2018. PMID: 29161986.
86. Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. J Clin Oncol 36(1):JCO2017736785, 2018. e-Pub 2018. PMID: 29072975.
87. Tam S, Amit M, Boonsripitayanon M, Cabanillas ME, Busaidy NL, Gunn GB, Lai SY, Gross ND, Sturgis EM, Zafereo ME. Adjuvant External Beam Radiotherapy in Locally Advanced Differentiated Thyroid Cancer. JAMA Otolaryngol Head Neck Surg 143(12):1244-1251, 2017. e-Pub 2017. PMID: 29098272.
88. Cabanillas ME, de Souza JA, Geyer S, Wirth LJ, Menefee ME, Liu SV, Shah K, Wright J, Shah MH. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial. J Clin Oncol 35(29):JCO2017730226, 2017. e-Pub 2017. PMID: 28817373.
89. Cote GJ, Evers C, Hu MI, Grubbs EG, Williams MD, Hai T, Duose DY, Houston MR, Bui JH, Mehrotra M, Waguespack SG, Busaidy NL, Cabanillas ME, Habra MA, Luthra R, Sherman SI. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma. J Clin Endocrinol Metab 102(9):3591-3599, 2017. e-Pub 2017. PMID: 28911154.
90. Voss RK, Feng L, Lee JE, Perrier ND, Graham PH, Hyde SM, Nieves-Munoz F, Cabanillas ME, Waguespack SG, Cote GJ, Gagel RF, Grubbs EG. Medullary Thyroid Carcinoma in MEN2A: ATA Moderate or High-Risk RET Mutations Do Not Predict Disease Aggressiveness. J Clin Endocrinol Metab 102(8):2807-2813, 2017. e-Pub 2017. PMID: 28609830.
91. Cabanillas ME, Williams MD, Gunn GB, Weitzman SP, Burke L, Busaidy NL, Ying AK, Yiin YH, William WN, Lu C, Lai SY. Facilitating anaplastic thyroid cancer specialized treatment: A model for improving access to multidisciplinary care for patients with anaplastic thyroid cancer. Head Neck 39(7):1291-1295, 2017. e-Pub 2017. PMID: 28452157.
92. Pezzi TA, Mohamed ASR, Sheu T, Blanchard P, Sandulache VC, Lai SY, Cabanillas ME, Williams MD, Pezzi CM, Lu C, Garden AS, Morrison WH, Rosenthal DI, Fuller CD, Gunn GB. Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base. Cancer 123(9):1653-1661, 2017. e-Pub 2017. PMID: 28026871.
93. Rao SN, Zafereo M, Dadu R, Busaidy NL, Hess K, Cote GJ, Williams MD, William WN, Sandulache V, Gross N, Gunn GB, Lu C, Ferrarotto R, Lai SY, Cabanillas ME. Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma. Thyroid 27(5):672-681, 2017. e-Pub 2017. PMID: 28068873.
94. Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Heymach JV, Sharma P, Naing A, Hong DS. Ipilimumab with stereotactic ablative radiation therapy: Phase I results and immunologic correlates from peripheral T-cells. Clin Cancer Res 23(6):1388-1396, 2017. e-Pub 2017. PMID: 27649551.
95. Sandulache VC, Williams MD, Lai SY, Lu C, William WN, Busaidy NL, Cote GJ, Singh RR, Luthra R, Cabanillas ME. Real-time genomic characterization utilizing circulating cell-free DNA in patients with anaplastic thyroid carcinoma. Thyroid 27(1):81-87, 2017. e-Pub 2017. PMID: 27785980.
96. Xu JY, Murphy WA, Milton DR, Jimenez C, Rao SN, Habra MA, Waguespack SG, Dadu R, Gagel RF, Ying AK, Cabanillas ME, Weitzman SP, Busaidy NL, Sellin RV, Grubbs E, Sherman SI, Hu MI. Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma. J Clin Endocrinol Metab 101(12):jc20162815, 2016. e-Pub 2016. PMID: 27662441.
97. Xu JY, Handy B, Michaelis CL, Waguespack SG, Hu MI, Busaidy N, Jimenez C, Cabanillas ME, Fritsche HA, Cote GJ, Sherman SI. Detection and Prognostic Significance of Circulating Tumor Cells in Patients with Metastatic Thyroid Cancer. J Clin Endocrinol Metab 101(11):jc20162567, 2016. e-Pub 2016. PMID: 27575943.
98. Grubbs EG, Williams MD, Scheet P, Vattathil S, Perrier ND, Lee JE, Gagel RF, Hai T, Feng L, Cabanillas ME, Cote GJ. The role of CDKN2C copy number in sporadic medullary thyroid carcinoma. Thyroid 26(11):1553-1562, 2016. e-Pub 2016. PMID: 27610696.
99. Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ. Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol 17(9):1272-82, 2016. e-Pub 2016. PMID: 27460442.
100. Bernstein MB, Chang EL, Amini B, Pan H, Cabanillas M, Wang XA, Allen PK, Rhines LD, Tatsui C, Li J, Brown PD, Ghia AJ. Spine Stereotactic Radiosurgery for Patients with Metastatic Thyroid Cancer: Secondary Analysis of Phase I/II Trials. Thyroid 26(9):1269-75, 2016. e-Pub 2016. PMID: 27334245.
101. Pezzi TA, Sandulache VC, Pezzi CM, Turkeltaub AE, Feng L, Cabanillas ME, Williams MD, Lai SY. Treatment and survival of patients with insular thyroid carcinoma: 508 cases from the National Cancer Data Base. Head Neck 38(6):906-12, 2016. e-Pub 2016. PMID: 26843481.
102. Danysh BP, Rieger EY, Sinha DK, Evers CV, Cote GJ, Cabanillas ME, Hofmann MC. Long-Term Vemurafenib Treatment Drives Inhibitor Resistance Through a Spontaneous KRAS G12D Mutation in a BRAF V600E Papillary Thyroid Carcinoma Model. Oncotarget 7(21):30907-23, 2016. e-Pub 2016. PMID: 27127178.
103. Ozsari L, Kutahyalioglu M, Elsayes KM, Vicens RA, Sircar K, Jazaerly T, Waguespack SG, Busaidy NL, Cabanillas ME, Dadu R, Hu MI, Vassilopoulou-Sellin R, Jimenez C, Lee JE, Habra MA. Preexisting adrenal masses in patients with adrenocortical carcinoma: clinical and radiological factors contributing to delayed diagnosis. Endocrine 51(2):351-9, 2016. e-Pub 2016. PMID: 26206754.
104. Schlumberger M, Jarzab B, Cabanillas ME, Robinson B, Pacini F, Ball DW, McCaffrey J, Newbold K, Allison R, Martins RG, Licitra LF, Shah MH, Bodenner D, Elisei R, Burmeister L, Funahashi Y, Ren M, O'Brien JP, Sherman SI. A Phase 2 Trial of the Multi-targeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer (MTC). Clin Cancer Res 22(1):44-53, 2016. e-Pub 2016. PMID: 26311725.
105. Dadu R, Hu MI, Cleeland C, Busaidy NL, Habra M, Waguespack SG, Sherman SI, Ying A, Fox P, Cabanillas ME. Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study. Thyroid 25(10):1085-90, 2015. e-Pub 2015. PMID: 26200040.
106. Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, McCaffrey JC, Shah MH, Bodenner DL, Topliss D, Andresen C, O'Brien JP, Ren M, Funahashi Y, Allison R, Elisei R, Newbold K, Licitra LF, Sherman SI, Ball DW. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer 121(16):2749-56, 2015. e-Pub 2015. PMID: 25913680.
107. Falchook GS, Millward M, Hong D, Naing A, Piha-Paul S, Waguespack SG, Cabanillas ME, Sherman SI, Ma B, Curtis M, Goodman V, Kurzrock R. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid 25(1):71-7, 2015. e-Pub 2015. PMID: 25285888.
108. Dadu R, Shah K, Busaidy NL, Waguespack SG, Habra MA, Ying AK, Hu MI, Bassett R, Jimenez C, Sherman SI, Cabanillas ME. Efficacy and Tolerability of Vemurafenib in Patients with BRAFV600E -Positive Papillary Thyroid Cancer: M.D. Anderson Cancer Center off label experience. J Clin Endocrinol Metab 100(1):E77-81, 2015. e-Pub 2015. PMID: 25353071.
109. Cabanillas ME, Hu MI, Jimenez C. Medullary thyroid cancer in the era of tyrosine kinase inhibitors: to treat or not to treat--and with which drug--those are the questions. J Clin Endocrinol Metab 99(12):4390-6, 2014. e-Pub 2014. PMID: 25238206.
110. Cabanillas ME, Brose MS, Holland J, Ferguson KC, Sherman SI. A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer. Thyroid 24(10):1508-14, 2014. e-Pub 2014. PMID: 25102375.
111. Dadu R, Devine C, Hernandez M, Waguespack SG, Busaidy NL, Hu MI, Jimenez C, Habra MA, Sellin RV, Ying AK, Cote GJ, Sherman SI, Cabanillas ME. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab 99(6):2086-94, 2014. e-Pub 2014. PMID: 24628550.
112. Blevins DP, Dadu R, Hu M, Baik C, Balachandran D, Ross W, Gunn B, Cabanillas ME. Aero-digestive Fistula Formation as a Rare Side Effect of Antiangiogenic Tyrosine Kinase Inhibitor Therapy for Thyroid Cancer. Thyroid 24(5):918-22, 2014. e-Pub 2014. PMID: 24635127.
113. Holsinger FC, Ramaswamy U, Cabanillas ME, Lang J, Lin HY, Busaidy NL, Grubbs E, Rahim S, Sturgis EM, Lee JE, Weber RS, Clayman GL, Rohren EM. Measuring the Extent of Total Thyroidectomy for Differentiated Thyroid Carcinoma Using Radioactive Iodine Imaging: Relationship With Serum Thyroglobulin and Clinical Outcomes. JAMA Otolaryngol Head Neck Surg 140(5):410-5, 2014. e-Pub 2014. PMID: 24700275.
114. Dadu R, Waguespack SG, Sherman SI, Hu MI, Busaidy NL, Jimenez C, Habra MA, Ying AK, Bassett RL, Cabanillas ME. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. Oncologist 19(5):477-82, 2014. e-Pub 2014. PMID: 24733667.
115. Thomas L, Lai SY, Dong W, Feng L, Dadu R, Regone RM, Cabanillas ME. Sorafenib in metastatic thyroid cancer: a systematic review. Oncologist 19(3):251-8, 2014. e-Pub 2014. PMID: 24563075.
116. Kim KB, Cabanillas ME, Lazar AJ, Williams MD, Sanders DL, Ilagan JL, Nolop K, Lee RJ, Sherman SI. Clinical responses to Vemurafenib in Patients with Metastatic Papillary Thyroid Cancer Harboring V600E BRAF mutation. Thyroid 23(10):1277-83, 2013. e-Pub 2013. PMID: 23489023.
117. Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, Ying A, Vassilopoulou-Sellin R, Gagel RF, Sherman SI, Busaidy NL. The Non-investigational Use of Tyrosine Kinase inhibitors in Thyroid Cancer: Establishing a Standard for Patient Safety and Monitoring. J Clin Endocrinol Metab 98(1):31-42, 2013. e-Pub 2013. PMID: 23185034.
118. Hightower E, Cabanillas ME, Fuller GN, McCutcheon IE, Hess KR, Shah K, Waguespack SG, Corley LJ, Devin JK. Phospho-histone H3 (PHH3) Immuno-reactivity as a Prognostic Marker in Non-Functioning Pituitary Adenomas. Pituitary 15(4):556-61, 2012. e-Pub 2012. PMID: 22120760.
119. Ayala-Ramirez M, Chougnet CN, Habra MA, Palmer JL, Leboulleux S, Cabanillas ME, Caramella C, Anderson P, Al Ghuzlan A, Waguespack SG, Deandreis D, Baudin E, Jimenez C. Treatment with Sunitinib for Patients with Progressive Metastatic Pheochromocytomas and Sympathetic Paragangliomas. J Clin Endocrinol Metab 97(11):4040-50, 2012. e-Pub 2012. PMID: 22965939.
120. Vu K, Busaidy N, Cabanillas ME, Konopleva M, Faderl S, Thomas DA, O'Brien S, Broglio K, Ensor J, Escalante C, Andreeff M, Kantarjian H, Lavis V, Yeung SC. A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 12(5):355-62, 2012. e-Pub 2012. PMID: 22658895.
121. Del Fabbro E, Dev R, Cabanillas ME, Busaidy NL, Rodriguez EC, Bruera E. Extreme hypothyroidism associated with sunitinib treatment for metastatic renal cancer. J Chemother 24(4):221-5, 2012. e-Pub 2012. PMID: 23040687.
122. Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE. Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: Results of a Randomized Clinical Trial. Cancer 118(3):848-55, 2012. e-Pub 2012. PMID: 21751205.
123. Busaidy NL, Cabanillas ME. Differentiated thyroid cancer: management of patients with radioiodine non-responsive disease. J Thyroid Res 2012:618985, 2012. e-Pub 2012. PMID: 22530159.
124. Ejaz S, Vassilopoulou-Sellin R, Busaidy NL, Hu MI, Waguespack SG, Jimenez C, Ying AK, Cabanillas M, Abbara M, Habra MA. Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: The University of Texas MD Anderson Cancer Center Experience. Cancer 117(19):4381-9, 2011. e-Pub 2011.
125. Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Busaidy NL, Waguespack SG, Hernandez M, El Naggar AK, El Naggar AK, Bidyasar S, Wright J, Sherman SI, Kurzrock R. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab 96(4):997-1005, 2011. e-Pub 2011. PMID: 21289252.
126. Mattiuzzi GN, Cortes JE, Blamble DA, Bekele BN, Xiao L, Cabanillas M, Borthakur G, O'Brien S, Kantarjian H. Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Cancer, 2010. e-Pub 2010.
127. Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI, Busaidy NL. Treatment with Tyrosine Kinase Inhibitors for Patients with Differentiated Thyroid Cancer the M.D. Anderson Experience (selected for editorial in Nature Reviews and J Clin Endocrinol Metab). J Clin Endocrinol Metab 95(6):2621-4, 2010. e-Pub 2010. PMID: 20392874.
128. Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA, Matin SF, Nunez RF, Perrier ND, Phan A, Rich TA, Shah B, Williams MD, Waguespack SG. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab 94(2):386-91, 2009. e-Pub 2009. PMID: 19017755.
129. Torres HA, Aguilera EA, Mattiuzzi GN, Cabanillas ME, Rohatgi N, Sepulveda CA, Kantarjian HM, Jiang Y, Safdar A, Raad II, Chemaly RF. Characteristics and outcomes of respiratory syncytial virus infection in patients with leukemia. Haematologica 92(9):1216-23, 2007. e-Pub 2007. PMID: 17666367.
130. Chemaly RF, Torres HA, Aguilera EA, Mattiuzzi G, Cabanillas M, Kantarjian H, Gonzalez V, Safdar A, Raad II. Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study. Clin Infect Dis 44(7):964-7, 2007. e-Pub 2007. PMID: 17342649.
131. Jabbour E, O'Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, Cabanillas M, Thomas DA. Neurological complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood, 2007. e-Pub 2007. PMID: 17209054.
132. Weiser MA, Cabanillas M, Vu K, Tamm EP, Wallace MJ, Escalante CP, Bresalier RS. Diagnostic evaluation of patients with a high suspicion of malignancy: comorbidities and clinical predictors of cancer. Am J Med Sci 330(1):11-8, 2005. e-Pub 2005. PMID: 16020994.
133. Jozaghi Y, Chaudhri A, Zafereo M, Fellman B, Dadu R, Busaidy N, Iyer P, Williams M, Wang J, Roy-Chowdhuri S, Cabanillas M. Immunohistochemical Testing versus Next Generation Sequencing for Identification of BRAF V600E Mutations in Clinical Practice for Anaplastic Thyroid Cancer.

Invited Articles

1. Gulec SA, Benites C, Cabanillas ME. Molecular Perspectives in Radioactive Iodine Theranostics: Current Redifferentiation Protocols for Mis-Differentiated Thyroid Cancer. Journal of Clinical Medicine 13(13), 2024. e-Pub 2024. PMID: 38999211.
2. # NT, # SH, Ouni R, Rico R, Henderson YC, Puche M, Alekseev S, Colunga-Minutti JG, Zafereo ME, Lai SY, Kim ST, Cabanillas ME, Nurieva R. Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy. Frontiers in immunology 15, 2024. e-Pub 2024. PMID: 38868771.
3. Boucai L, Zafereo M, Cabanillas ME. Thyroid Cancer: A Review. JAMA 331(5):425-435, 2024. e-Pub 2024. PMID: 38319329.
4. Landa I, Cabanillas ME. Genomic alterations in thyroid cancer: biological and clinical insights. Nat Rev Endocrinol 20(2):93-110, 2024. e-Pub 2024. PMID: 38049644.
5. Haddad R, Elisei R, Hoff AO, Liu Z, Pitoia F, Pruneri G, Sadow PM, Soares F, Turk A, Williams MD, Wirth LJ, Cabanillas ME. Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid Carcinomas: A Review. JAMA Oncol 9(8):1132-1141, 2023. e-Pub 2023. PMID: 37289450.
6. Cabanillas, ME, Iyer, PC, Hu, MI. A Decade of Progress in Targeted Therapy for Advanced Thyroid Cancer. Endocrine Practice 29(3):221-227, 2023. e-Pub 2023.
7. Hamidi S, Hofmann MC, Iyer PC, Cabanillas ME, Hu MI, Busaidy NL, Dadu R. Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance. Front Endocrinol (Lausanne) 14:1176731, 2023. e-Pub 2023. PMID: 37435488.
8. Cabanillas ME, Ahmed S, Wang JR. Management of Anaplastic and Recurrent Differentiated Thyroid Cancer: Indications for Surgical Resection, Molecular Testing, and Systemic Therapy. Neuroimaging Clin N Am 31(3):359-366, 2021. e-Pub 2021. PMID: 34243870.
9. Cabanillas ME, Ryder M, Jimenez C. Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond. Endocr Rev 40(6):1573-1604, 2019. e-Pub 2019. PMID: 31322645.
10. Cabanillas ME, Iyer PC, Hu M. A Decade of Progress in Targeted Therapy for Advanced Thyroid Cancer: An Overview. Endocrine Practice, 2019. e-Pub 2019. PMID: 31322645.
11. Cabanillas ME, Takahashi S. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer. Semin Oncol 46(1):57-64, 2019. e-Pub 2019. PMID: 30685073.
12. Cabanillas ME, Rao SN. Navigating systemic therapy in advanced thyroid carcinoma: from standard-of-care to personalized therapy and beyond. Journal of the Endocrine Society, 2018. e-Pub 2018.
13. Cabanillas ME, Zafereo M, Williams MD, Ferrarotto R, Dadu R, Gross N, Gunn GB, Skinner H, Cote G, Grosu HB, Iyer P, Busaidy NL. Recent advances and emerging therapies in anaplastic thyroid carcinoma. F1000 Faculty Reviews 7(87), 2018. e-Pub 2018.
14. Cabanillas ME, McFadden DG, Durante C. Thyroid Cancer. Lancet 388(10061):2783-2795, 2016. e-Pub 2016. PMID: 27240885.
15. Cabanillas ME, Busaidy NL, Khan SA, Brandon Gunn G, Dadu R, Rao SN, Waguespack SG. Molecular diagnostics and anaplastic thyroid carcinoma: the time has come to harvest the high hanging fruit. International Journal of Endocrine Oncology, 2016. e-Pub 2016.
16. Cabanillas ME, Zafereo M, Gunn GB, Ferrarotto R. Anaplastic Thyroid Carcinoma: Treatment in the Age of Molecular Targeted Therapy. J Oncol Pract 12(6):511-8, 2016. e-Pub 2016. PMID: 27288464.
17. Cabanillas ME, Habra MA. Lenvatinib: Role in thyroid cancer and other solid tumors. Cancer Treat Rev 42:47-55, 2016. e-Pub 2016. PMID: 26678514.
18. Cabanillas ME, Dadu R, Hu MI, Lu C, Gunn GB, Grubbs EG, Lai SY, Williams MD. Thyroid Gland Malignancies. Hematol Oncol Clin North Am 29(6):1123-43, 2015. e-Pub 2015. PMID: 26568552.
19. Cabanillas ME, Patel A, Danysh BP, Dadu R, Kopetz S, Falchook G. BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity. Horm Cancer 6(1):21-36, 2015. e-Pub 2015. PMID: 25467940.
20. Weitzman SP, Cabanillas ME. The Treatment Landscape in Thyroid Cancer: a Focus on Cabozantinib. Cancer Manag Res 7:265-78, 2015. e-Pub 2015. PMID: 26316818.
21. Cabanillas ME, Hu MI, Jimenez C, Grubbs EG, Cote GJ. Treating medullary thyroid cancer in the age of targeted therapy. Int J Endocr Oncol 1(2):203-216, 2014. e-Pub 2014. PMID: 25908961.
22. Ganeshan D, Paulson E, Duran C, Cabanillas ME, Busaidy NL, Charnsangavej C. Current Update on Medullary Thyroid Carcinoma. AJR Am J Roentgenol 201(6):W867-76, 2013. e-Pub 2013. PMID: 24261394.
23. Dadu R, Cabanillas ME. Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: Current state of the art and future directions. Minerva Endocrinol 37(4):335-56, 2012. e-Pub 2012. PMID: 23235190.
24. Cabanillas ME, Hu MI, Durand JB, Busaidy NL. Challenges Associated with Tyrosine Kinase Inhibitor Therapy for Metastatic Thyroid Cancer. J Thyroid Res 2011:985780, 2011. e-Pub 2011. PMID: 22007339.
25. Rich TA, Cabanillas ME, Perrier ND, Waguespack SG. CDC73-Related Disorders: Hyperparathyroidism-Jaw Tumor Syndrome (HRPT2). Gene Reviews, 2008. e-Pub 2008.

Review Articles

1. Salim HA, Msherghi A, Learned K, Zafereo M, Wang J, Dagher SA, Altintas Taslicay C, Dagher R, Alizada S, Hu MI, Cabanillas ME, Busaidy N, Hamidi S, Tawbi H, Li J, Ucisik FE, Wintermark M. Prognostic Factors in Thyroid Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis. Thyroid, 2025. e-Pub 2025. PMID: 40956665.
2. Hamidi S, Maniakas A, Cabanillas ME. Advances in Anaplastic Thyroid Cancer Treatment. Endocrinol Metab Clin North Am 54(3):361-375, 2025. e-Pub 2025. PMID: 40716892.
3. Cabanillas ME, Akhave N, Banuchi V, Busaidy N, Dadu R, Ferrarotto R, Gunn GB, Hamidi S, Hofmann MC, Hosseini SM, Iyer PC, Lai SY, Lee A, Maniakas A, Ning MS, Spiotto M, Wang JR, Williams MD, Zafereo M. Reimagining the Therapeutic Approach for Anaplastic Thyroid Cancer: The Roadmap to a Cure. Thyroid 35(5):462-470, 2025. e-Pub 2025. PMID: 40388579.
4. Waguespack, SG, Cabanillas, ME, Bernard-Gauthier, V, Assar, N, Bloom, G, Esparza, R, Brose, MS. A plain language summary looking at how well larotrectinib works and how safe it is for people with TRK fusion-positive thyroid cancer. Future Oncology 21(2):169-179, 2025. e-Pub 2025. PMID: 39614411.
5. Nardo M, Gouda MA, Nelson BE, Barreto CMN, Slade JH, Poullard A, Zafereo M, Hu MI, Cabanillas ME, Subbiah V. Strategies for Mitigating Adverse Events Related to Selective RET Inhibitors in Patients with RET-altered Cancers. Cell Rep Med 4(12):101332, 2023. e-Pub 2023. PMID: 38118420.
6. Hofmann MC, Kunnimalaiyaan M, Wang JR, Busaidy NL, Sherman SI, Lai S, Zafereo M, Cabanillas ME. Molecular mechanisms of resistance to kinase inhibitors in thyroid cancers. Endocr Relat Cancer 29(11):R173-R190, 2022. e-Pub 2022. PMID: 35975971.
7. Maniakas, A, Zafereo, M, Cabanillas, ME. Anaplastic Thyroid Cancer. Endocrinology and Metabolism Clinics of North America 51(2):391-401, 2022. e-Pub 2022. PMID: 35662448.
8. Bible KC, Kebebew E, Brierley J, Brito JP, Cabanillas ME, Clark TJ, Di Cristofano A, Foote R, Giordano T, Kasperbauer J, Newbold K, Nikiforov YE, Randolph G, Rosenthal MS, Sawka AM, Shah M, Shaha A, Smallridge R, Wong-Clark CK. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid 31(3):337-386, 2021. e-Pub 2021. PMID: 33728999.
9. Fullmer T, Cabanillas ME, Zafereo M. Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer. Front Endocrinol (Lausanne) 12:720723, 2021. e-Pub 2021. PMID: 34335481.
10. Cabanillas M, Terris DJ, Sabra M. Information for Clinicians: Approach to the patient with progressive radioactive iodine refractory thyroid cancer- When to use systemic therapy. Thyroid, 2017. e-Pub 2017. PMID: 28635520.

Professional Educational Materials

1. Cabanillas ME. Anaplastic Thyroid Cancer: A Doctor’s Perspective for Patients and Families Living with the Disease. Thyca.org, 2015.
2. . Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. The Oncologist CME Online, 2014.
3. . Sorafenib in Metastatic Thyroid Cancer-A Systematic Review. The Oncologist, CME Online, 2014.

Other Articles

1. Marczyk VR, Fazeli S, Dadu R, Busaidy NL, Iyer P, Hu MI, Sherman SI, Hamidi S, Hosseini SM, Williams MD, Ahmed S, Routbort MJ, Luthra R, Roy-Chowdhuri S, San Lucas FA, Patel KP, Hong DS, Zafereo M, Wang JR, Maniakas A, Waguespack SG, Cabanillas ME Erratum: NTRK Fusion-Positive Thyroid Carcinoma: From Diagnosis to Targeted Therapy. JCO Precis Oncol 9:e2500552, 2025. PMID: 40632979.
2. Boucai, L, Zafereo, M, Cabanillas, ME A Review of Thyroid Cancer. JAMA 331(21):1863-1864, 2024. PMID: 38709520.
3. Srivastava A, Nogueras Gonzalez GM, Geng Y, Won AM, Cabanillas ME, Naing A, Myers JN, Li Y, Chambers MS Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis. Support Care Cancer 29(5):2305-2317, 2021. PMID: 33190182.

Editorials

1. Cabanillas ME, Busaidy NL, Sherman SI. Redifferentiation therapy-Returning to our roots in a post-kinase inhibitor world. Clin Cancer Res 28(19):4164-4166, 2022. PMID: 35895318.

Abstracts

1. Ebrahimi S, Hamidi S, Baser HD, Ryoo Ali HJ, Koutroumpakis E, Kumar S, Cabanillas ME, Dadu R, Iyer PC, Hu MI, Busaidy NL, Waguespack SG, Mouhayar EN, Palaskas NL, Deswal A. Emergence of Hypertension in Thyroid Cancer Patients on BRAF ± MEK Inhibitors: A Closer Look at Incidence and Contributing Risk Factors. 2025 American Heart Association Annual Meeting 2025; Accepted/In press. 2025 American Heart Association Annual Meeting, 2025. e-Pub 2025.
2. Sarah Hamidi MD, Maria Cabanillas MD, Ramona Dadu MD, Mimi Hu MD, Steven Waguespack MD, Naifa Busaidy MD, MBBS PI, Melinda Vickers MS, Ann Uy RN, Sonal Gupta MD, Deyaa Adib MD, Maria Gule-Monroe MD, MD ChB SS. Safety and Efficacy of Second Dose of AIC100 CAR T-cell in Patients with Poorly Differentiated (PDTC) andAanaplastic Thyroid Carcinoma (ATC). 2025 American Thyroid Association Annual Meeting, 2025. e-Pub 2025.
3. Arpi Palacios JE, Fournier I, Maniakas A, Wang JR, Banuchi VE, Lango MN, Gule-Monroe MC, Williams MD, Mena M, Grubbs EG, Fisher SB, Xu L, Busaidy NL, Cabanillas ME, Castellanos LE, Dadu R, Hamidi S, Hu MI, Waguespack SG, Zafereo ME. Neoadjuvant Targeted Therapy for Locally Advanced Differentiated Thyroid Carcinoma. 2025 American Thyroid Association Annual Meeting 2025 Sep; Accepted/In press. 2025 American Thyroid Association Annual Meeting, 2025. e-Pub 2025.
4. Cabanillas ME, Busaidy NL, Iyer PC, Wang JR, Hu MI, Zafereo ME, Ferrarotto R, Lee A, Liu S, Gunn GB, Spiotto M, Hamidi S, Akhave N, de Sousa L, Maniakas A, Williams MD, Banuchi VE, Hosseini SM, Dadu R. Lenvatinib (LEN) plus Pembrolizumab (PEMBRO) in Anaplastic Thyroid Cancer (ATC): A Phase 2, Single Center Trial. 2025 American Thyroid Association Annual Meeting, 2025. e-Pub 2025.
5. Arpi Palacios JE, Hamidi S, Abubaker A, Cabanillas ME, Dadu R, Iyer PC, Busaidy NL, Zafereo ME, Wang JR, Banuchi VE, Gunn GB, Lee A, Ahmed S, Kwon M, Williams MD, Mansour M, Maniakas A. Clinicopathological Features of Papillary Thyroid Cancer (PTC)-to-Anaplastic Thyroid Carcinoma (ATC) Transformation. 2025 American Thyroid Association Annual Meeting, 2025. e-Pub 2025.
6. Hamidi S, Busaidy NL, Iyer PC, Dadu R, Gule-Monroe R, Maniakas A, Wang JR, Banuchi V, Zafereo ME, Cabanillas ME. Addition of VEGF or mTOR Inhibition to BRAF-targeted Therapy in BRAFV600E-mutated ATC. 2025 American Thyroid Association Annual Meeting, 2025. e-Pub 2025.
7. Zafereo ME, Cabanillas ME, Maniakas A, Wang JR, Chinn SB, Mady LJ, Fisher SB, Graham PH, Grubbs EG, Seim NB, Banuchi VE, Gule-Monroe MC, Williams MD, Xu L, Busaidy NL, Dadu R, Hamidi S, Iyer PC, Waguespack SG, Sherman SI, Nabhan FS, Ball DW, Worden FP, Hu MI. Neoadjuvant Treatment with Selpercatinib for RET-Altered Thyroid Cancer: A Multicenter Phase 2 Clinical Trial. 2025 American Thyroid Association Annual Meeting, 2025. e-Pub 2025.
8. Ahmad Abubaker MD, Isabelle Fournier MD, Mark Zafereo MD, Jennifer R Wang MD, Victoria Banuchi MD, Elizabeth G Grubbs MD, Paul H Graham MD, Naifa L Busaidy MD, Maria E Cabanillas MD, Ramona Dadu MD, Sarah Hamidi MD, Mimi I Hu MD, Priyanka Iyer MD, Steven I Sherman MD, Steven G Waguespack MD, Sachin Kumar Gupta MS, Salmaan Ahmed MD, Michael Kwon MD, Michelle D Williams MD, S Mohsen Hosseini MD, Anastasios Maniakas MD. Surgical Management of Isthmus-confined Papillary Thyroid Carcinoma: A single Institution Retrospective Cohort Study. 2025 American Thyroid Association Annual Meeting, 2025. e-Pub 2025.
9. Fournier I, Maniakas A, Wang JR, Banuchi V, Lai SY, Gule-Monroe MK, Ning MS, Williams MD, Li X, Dadu R, Busaidy NL, Iyer PC, Hamidi S, Cabanillas ME, Zafereo ME. Neoadjuvant BRAF/MEK inhibitor therapy and immunotherapy for BRAFV600E-mutated anaplastic thyroid cancers. AHNS 2025 Annual Meeting, 2025. e-Pub 2025.
10. Fournier I, Waguespack SG, Castellanos L, Iyer P, Hamidi S, Busaidy NL, Cabanillas ME, Dadu R, Hu MI, Williams MD, Palacios JA, Monroe MG, Banuchi VE, Wang JR, Maniakas A, Zafereo ME. Neoadjuvant Larotrectinib Before Surgery For NTRK Fusion-Positive Thyroid Cancer: A Case Series. 17th International Thyroid Congress Scientific Program 2025 Jun 18; Endocrinology and Metabolism, 2025. e-Pub 2025.
11. Hamidi S, Vodopivec DM, Busaidy NL, Gule-Monroe MK, Akhave NS, Banuchi VE, Ferraroto R, Gunn G, Iyer PC, Lee A, Maniakas A, Ning MS, Sousa LG, Spiotto MT, Waguespack SG, Wang JR, Zafereo ME, Cabanillas ME, Dadu R. Real-World Experience With Lenatinib Plus Pembrolizumab In Metastatic BRAF Wild -Type Anaplastic Thyroid Carcinoma (BRAFWT-ATC). 17th International Thyroid Congress Scientific Program 2025 Jun 18; Endocrinology and Metabolism, 2025. e-Pub 2025.
12. Fournier I, Jorge Eduardo AP, Mahmoud Innab MK, Zafereo ME, Wang JR, Gross ND, Lango MN, Goepfert RP, Sturgis EM, Grubbs EG, Graham PH, Gupta SK, Busaidy NL, Cabanillas ME, Dadu R, Hamidi S, Hu MI, Iyer P, Waguespack S, Ahmed S, Kwon M, Banuchi VE, Maniakas A, Hosseini SM, Williams MD. Prognostic Significance of BRAFV600E Status In Patients Diagnosed With Papillary Thyroid Cancer (PTC). 17th International Thyroid Congress Scientific Program 2025 Jun 18; Endocrinology and Metabolism, 2025. e-Pub 2025.
13. Marczyk VR, Hamidi S, Zafereo M, Waguespack SG, Dadu R, Busaidy NL, Iyer PC, Maniakas A, Banuchi V, Cabanillas ME, Wang JR. Characterization Of The Genomic Landscape Of BRAF-, RAS-, And Fusion-Negative Thyroid Carcinomas Underscores The Role Of Tumor Suppressor Genes Available. 17th International Thyroid Congress Scientific Program 2025, 2025. e-Pub 2025.
14. Iyer PC, Wang JR, Hamidi S, Busaidy NL, Ferrarotto R, Akhave NS, Sousa LG, Gunn GB, Spiotto MT, Huang Q, Cabanillas ME. GRASSROOT- Global Real-world data in patients with Advanced thyroid cancer on Standard of care and Specialized Interventions- Registry of Oncologic Outcomes with Testing and treatment. Annals of Oncology, 2024. e-Pub 2024.
15. Ning MS, Dudzinski SO, Busaidy NL, Dadu R, Hamidi S, Welsh J, Gunn B, Waguespack SG, Hu MI, Marczyk VR, Spiotto M, Phan J, Reddy JP, Lee A, Ludmir EB, Maniakas A, Iyer P, Beckham T, Zafereo MA, E Cabanillas AM. Consolidative radiotherapy for oligometastatic and oligoprogressive anaplastic thyroid carcinoma: the potential utility of local therapy for limited distant sites. 2024 American Thyroid Association Annual Meeting, 2024. e-Pub 2024.
16. FHamidi S, Dadu R, Zafereo ME, Wang JR, Roy-Chowdhuri S, Williams MD, Ferrarotto R, Akhave NS, Sousa LG, Iyer PC, Marczyk VR, Guise TA, Hofmann M, Busaidy NL, Maniakas A, Cabanillas ME. Characterization of RAS-mutant Anaplastic Thyroid Carcinoma. 2024 American Thyroid Association Annual Meeting, 2024. e-Pub 2024.
17. Houl JH, Yarmand R, Mendez PM, Henderson Y, Wang JR, Hamidi S, Maniakas A, Iyer PC, Lai SY, Cabanillas M, Busaidy NL, Dadu R, Zafereo M, Hofmann AM. Role of ETV5/p38 signaling Axis in BRAF-Mutated. 2024 American Thyroid Association Annual Meeting 2024, 2024. e-Pub 2024.
18. Houl JH, Mendez PM, Wang JR, Hamidi S, Maniakas A, Iyer PC, Lai SY, Cabanillas M, Busaidy NL, Dadu R, Zafereo M, Hofmann AM. Targeting the MAPK and DNA Repair Pathways in Poorly Differentiated and Anaplastic Thyroid Cancer Cells. 2024 American Thyroid Association Annual Meeting Thyroid, 2024. e-Pub 2024.
19. Abdallah D, Hamidi S, Dadu R, Busaidy NL, Iyer PC, Waguespack SG, Zafereo ME, Cabanillas ME. Fusion-Driven Anaplastic Thyroid Cancer (ATC): Characterization and Clinical Outcomes. 2024 American Thyroid Association Annual Meeting Thyroid, 2024. e-Pub 2024.
20. Abubaker A, Henderson Y, Wang JR, Zafereo M, Banuchi V, Goswami M, Cabanillas ME, Busaidy N, Dadu R, Iyer P, Hamidi S, Williams M, Hosseini S, Lai SY, Maniakas A. Challenges and factors affecting successful patient-derived xenograft model establishment for anaplastic thyroid cancer. 2024 American Thyroid Association Annual Meeting Thyroid, 2024. e-Pub 2024.
21. Hamidi S, Maniakas A, Roy-Chowdhuri S, Hosseini S, Dadu R, Waguespack SG, Hu MI, Sherman SI, Iyer PC, Marczyk VR, Guise TA, Hofmann MC, Busaidy NL, Wang JR, Zafereo ME, Cabanillas ME. Clinicopathological Features of Advanced, RAS-driven Differentiated Thyroid Carcinoma. 2024 American Thyroid Association Annual Meeting, 2024. e-Pub 2024.
22. Castellanos LE, Hamidi S, Busaidy NL, Cabanillas ME, Dadu R, Hu MI, Iyer PC, Roy-Chowdhuri S, Sherman SI, Sura G, Wang JR, Williams MD, Iorgulescu JBL, Waguespack SGL. RAF Family Fusions in Thyroid Carcinomas: Clinicopathological Analysis of 16 Patients. 2024 American Thyroid Association Annual Meeting, 2024. e-Pub 2024.
23. Hamidi S, Dadu R, Ferrarotto R, Gule-Monroe M, Liu S, Fellman BM, Williams MD, Zafereo ME, Wang RJ, Lu C, Ning MS, McKinley B, Woodman SE, Duose DY, Gunn GB, Busaidy NL, Cabanillas ME. Cobimetinib plus atezolizumab for RAS and NF1/2-mutated poorly differentiated thyroid carcinoma. 2024 ASCO Annual Meeting. e-Pub 2024.
24. Hamidi S, Dadu R, Ferrarotto R, Gule-Monroe M, Liu S, Fellman BM, Williams MD, Zafereo ME, Wang RJ, Lu C, Ning MS, McKinley B, Woodman SE, Duose DY, Gunn GB, Busaidy NL, Cabanillas ME. Atezolizumab plus taxane chemotherapy for the treatment of non-BRAF, non-RAS mutated anaplastic thyroid carcinoma. ASCO Annual Meeting, 2024. e-Pub 2024.
25. Hamidi S, Dadu R, Ferrarotto R, Gule-Monroe M, Liu S, Fellman B, Williams MD, Zafereo ME, Wang JR, Lu C, Ning M, McKinley BA, Woodman SE, Duose D, Gunn GB, Busaidy NL, Cabanillas ME. Cobimetinib plus Atezolizumab for RAS and NF1/2-mutated Poorly Differentiated Thyroid Carcinoma, 2024. e-Pub 2024.
26. Hosseini S, MD, PhD, Zafereo ME, MD, Cabanillas ME, MD. Mutational Profiling of Anaplastic Thyroid Carcinoma Using Targeted Next-Generation, 2024. e-Pub 2024.
27. Cubb TD, Hamidi S, Gule-Monroe MK, Busaidy NL, Iyer PC, Shaw KR, Roy-Chowdhuri S, Sura GH, Zafereo ME, Wang JR, Banuchi VE, Maniakas A, Cabanillas ME. Effect of PI3K Pathway Activating Mutations (PI3Kpath-mutation) on Response to BRAF/MEK Inhibitor (BRAF/MEKi) Therapy in BRAFV600E Mutated Anaplastic Thyroid Cancer (BRAFV600Em-ATC). Thyroid 2024, 2024. e-Pub 2024.
28. Hamidi S, Iyer PC, Gule-Monroe MK, Maniakas A, Dadu R, Zafereo ME, Wang J, Busaidy NL, Cabanillas ME. Efficacy of adding anti-PD1 immunotherapy to dabrafenib + trametinib (DT) at progression in BRAFv600e mutated anaplastic thyroid carcinoma (BRAFm-ATC). Society for Immunotherapy of Cancer 38th Annual Meeting, 2023. e-Pub 2023.
29. Ning M, Dudzinski S, Busaidy N, Dadu R, Welsh J, Hu M, Hamidi S, Marczyk VR, Gunn B, Wang C, Waguespack S, Phan J, Beckham T, Chang J, Sherman S, Reddy J, Ying A, O'Reilly M, Chen A, Lee A, Gandhi S, Liao Z, Ludmir E, Nguyen Q, Tang C, Lin S, Zafereo M, Cabanillas M. Definitive Radiotherapy for Oligometastatic and Oligoprogressive Differentiated Thyroid Carcinoma: A Potential Strategy to Defer Escalation of Systemic Therapy. 2023 American Thyroid Association Annual Meeting, 2023. e-Pub 2023.
30. Hamidi S, Iyer P, Gule‐Monroe M, Maniakas A, Dadu R, Zafereo M, Wang J, Busaidy N, Cabanillas M. Checkpoint Inhibition in Addition to Dabrafenib + Trametinib for BRAFV600E Mutated Anaplastic Thyroid Carcinoma. 2023 American Thyroid Association Annual Meeting, 2023. e-Pub 2023.
31. Srour S, Cabanillas ME, Gupta S, Zafereo ME, Lu Y, Dadu R, Brana S, Cushing M, Avecilla S, Scognamiglio T, Jin M, Puc J, Liu G, Du K, Haider A, Mayer SA, Hsu J, Fahey TJ, Van Besien K. Safety and early efficacy results of phase 1 study of affinity tuned and trackable AIC100 CAR T cells in ICAM-1 positive relapsed and/or refractory advanced poorly differentiated and anaplastic thyroid cancers, 2023. e-Pub 2023.
32. Nelson BE, Gouda MA, Roszik J, Hu MI, Cabanillas ME, Subbiah V. Genomic Landscape of 2128 Thryoid Cancers from the AACR Genie Database: Implications for Targeted Therapies. AACR Annual Meeting 2023: Poster Session, 2023. e-Pub 2023.
33. Maniakas A, Wilde DC, Hyde EK, Xu L, Wang JR, Gross ND, Busaidy NL, Cabanillas ME, Iyer P, Dadu R, Gunn GB, Garden AS, Kwon M, Ahmed S, Williams MD, Zafereo ME. Segmental tracheal resection for thyroid cancer: Perioperative morbidity, locoregional control, and survival. e-Pub 2023.
34. Nelson BE, Roszik J, NOIA BARRETO CM, Nardo M, Ahmed J, Campbell E, Johnson A, Piha-Paul SA, Glitza IC, Weathers SS, Cabanillas ME, Javle MM, Meric-Bemstam F, Subbiah V. RAF-inhibitor rechallenge therapy in BRAF aberrated pan-cancers: RE-RAFFLE study. ASCO Annual Meeting 41(16):3105, 2023. e-Pub 2023.
35. Cabanillas ME, Gunn GB, Zafereo ME, Wang RJ, Iyer PC, Maniakas A, Spiotto MT, Dadu R. IMRT followed by pembrolizumab in the adjuvant setting in anaplastic cancer of the thyroid (IMPAACT): Phase II trial adjuvant pembrolizumab after IMRT in ATC. ASCO Annual Meeting, 2023. e-Pub 2023.
36. Vodopivec DM, Cabanillas ME, Busaidy NL, Gule-Monroe MK, Zafereo ME, Wang JR, Williams MD, Waguespack SG, Bassett R, Maniakas A, Lai SY, Dadu R. Single Center Experience with the Combination of Lenvatinib and Pembrolizumab for the Treatment of Anaplastic Thyroid Cancer, 2022. e-Pub 2022.
37. Tetlay M, Vodopivec D, Zafereo ME, Varghese JM, Cabanillas ME. Benralizumab stimulating growth of thyroid cancer by activating Graves’ Disease – A Case Report. 91st Annual Meeting of the American Thyroid Association, 2022. e-Pub 2022.
38. Vodopivec DM, Cabanillas ME. A personalized tumor-informed assay for detecting circulating tumor DNA in rare thyroid cancers: Proof-of-concept study, 2022. e-Pub 2022.
39. Fujiwara EM, Busaidy NL, Hai T, Cabanillas ME, Shah M, Ringel M, Hoffman MC. An Acquired Novel RAC1P34R Mutation Drives Proliferation and Actin Reorganization in Papillary Thyroid Cancer Cells but not Resistance to Dabrafenib, 2021. e-Pub 2021.
40. Bronk JK, Augustyn A, Mohamed AS, Wang R, Frank SJ, Fuller CD, Garden AS, Moreno AC, Morrison WH, Phan J, Reddy J, Rosenthal DI, Zafereo M, Ferrarotto R, Cabanillas ME, Gunn GB. Patterns Of Loco-Regional Failure And Outcomes After Intensity Modulated Radiation Therapy For Unresectable Anaplastic Thyroid Cancer 108(3):e849-e850, 2020. e-Pub 2020.
41. Cabanillas ME, Drilon A, Farago AF, Brose MS, McDermott R, Sohal D, Oh DY, Almubarak M, Bauman J, Chu E, Kummar S, Leyvraz S, Park K, Reeves JA, Dima L, Maeda P, Rodrigues L, Brega N, Hong DS, Waguespack SG. Larotrectinib treatment of advanced TRK fusion thyroid cancer, 2020. e-Pub 2020.
42. Brown SJ, Gruschkus SK, Waguespack SG, Dadu R, Zafereo M, Cabanillas ME, Grubbs EG, Sherman SI, Hu MI. RAS-Mutated Sporadic Medullary Thyroid Cancer: A Single-Center Experience, 2020. e-Pub 2020.
43. Fazeli S, Dadu R, Waguespack SG, Sherman SI, Busaidy NL, Hu MI, Jimenez C, Habra MA, Williams M, Altameemi L, Poropatich K, Routbort MJ, Luthra R, Patel KP, Cabanillas M. TRK-fusion Thyroid Cancer: Clinical Characteristics and Molecular Patterns. Journal of the Endocrine Society 4(Issue Supplement_1, April-May 2020), 2020. e-Pub 2020.
44. Wirth LJ, Brose MS, Sherman EJ, Misir S, Xie S, Almonte A, Ye W, Licitra L, Schlumberger M, Sherman SI, Cabanillas M. An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer. Journal of the Endocrine Society 4(Issue Supplement_1, April-May 2020), 2020. e-Pub 2020.
45. Shah MH, Sherman EJ, Robinson B, Solomon B, Kang H, Lorch JH, Worden F, Brose MS, Leboulleux S, Godbert Y, Meurer M, Morris J, Owonikoko TK, Tan DSW, Gautschi O, Patel J, Yang L, Kherani J, Cabanillas ME, Wirth LJ. Selpercatinib (LOXO-292) in Patients with RET-altered Thyroid Cancers, 2020. e-Pub 2020.
46. Cabanillas ME, Dadu R, Ferrarotto R, Liu S, Fellman B, Gross N, Gule-Monroe M, Lu C, Grosu H, Williams M, Duose D, Mallampati S, Dervin S, Mckenna Jr EF, Wang JR, Zafereo M, Busaidy NL. Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC), 2020. e-Pub 2020.
47. Mohamed AS, Henderson YC, Bell D, Williams MD, Scherer S, Clayman G, Zafereo M, Wang RJ, Cabanillas ME, Staphan C, Johnson FM. In vivo drug response evaluation in anaplastic thyroid cancer patient-derived tumor xenografts following high-throughput screening, 2020. e-Pub 2020.
48. Graham P, Habra MA, Jimenez C, Ying AK, Busaidy NL, Cabanillas ME, Zafereo M, Perrier ND, Grubbs EG, Gagel RF, Sherman SI, Hu MI. "Ectopic ACTH Secretion in Medullary Thyroid Cancer: A Case Series at a Cancer Center", 2019. e-Pub 2019.
49. Chaudhri A, Cabanillas ME, Dadu R, Busaidy NL, Cote G, Chowdhuri S. Immunohistochemical (IHC) Testing Versus Next Generation Sequencing (NGS) for Identification of BRAF V600E Mutations in Clinical Practice for Anaplastic Thyroid Cancer, 2019. e-Pub 2019.
50. Fazeli S, Guille-Monroe M, Cabanillas ME, Busaidy NL, Hu MI, Sherman SI, Waguespack SG, Jimenez C, Habra M, Cote G, Hoffman MC, Bassett R, Dadu R. Response to BRAF with/without MEK inhibitors in BRAFV600E plus TERT promoter mutated differentiated thyroid cancers, 2019. e-Pub 2019.
51. Falcone R, Waguespack SG, Dadu R, Sherman SI, Busaidy NL, Hu MI, Jimenez C, Weitzman SP, Cabanillas ME. Redifferentiation radioiodine (RAI)-therapy in patients (pts) with metastatic papillary, follicular and poorly differentiated thyroid cancer, 2019. e-Pub 2019.
52. Hu M, Cote G, Hai T, Busaidy N, Cabanillas ME, Dadu R, Gagel R, Grubbs E, Habra M, Jimenez C, Subbiah V, Waguespack S, Williams M, Zafereo M, Sherman S. Emergence of Resistance-Associated Mutatuibs if RET V804M and KRAS in Medullary Thyroid Carcinoma (MTC) Patients Treated with Tyrosine Kinase Inhibitors (TKI) Cabozantinib and Vandetanib, 2019. e-Pub 2019.
53. Maniakas A, Dadu R, Wang GR, Busaidy N, Hoffman MC, Sperling J, Gross N, Sturgis N, Geopfert R, Lai S, Cabanillas ME, Zafereo M. Revolutionizing the therapeutic landscape of a deadly disease, 2019. e-Pub 2019.
54. Falcone R, Waguespack S, Dadu R, Sherman S, Busaidy N, Hu M, Jimenez C, Weitzman S, Cabanillas ME. Redifferentiation radioiodine (RAI)-therapy in patients with metastatic papillary, follicular and poorly differentiated thyroid cancer (TC), 2019. e-Pub 2019.
55. Sperling J, Maniakas A, Cote G, Dadu R, Busaidy N, Lai S, Gross N, Goepfert R, Sturgis E, Zafereo M, Cabanillas ME, Wang RG. Prior cancers among patients newly diagnosed with anaplastic thyroid carcinoma: prevalence and impact on survival, 2019. e-Pub 2019.
56. Cabanillas ME, Busaidy N, Dadu R, Ferrarotto R, Gross N, Gule-Monroe M, Lu C, Grosu H, Williams M, Zafereo M. Combination Vemurafenib (BRAF Inhibitor)/Cobimetinib (MEK Inhibitor)/Atezolizumab (Anti-PDL1 Inhibitor) in BRAF-V600E Mutated Anaplastic Thyroid Cancer (ATC): Initial Safety and Feasibility. Journal of The Endocrine Society 3(Supplement_1, April-May 2019 OR27-6)), 2019. e-Pub 2019.
57. Agosto Salgado S, Cabanillas M. Brain Metastases in Thyroid Cancer: Molecular Profile and Institutional Experience of a Single Tertiary Referral Center in the Era of Kinase Inhibitor Therapy, 2019. e-Pub 2019.
58. Hu, MI, Cote, G, Hai, T, Busaidy, NL, Cabanillas, Grubbs ME, EG, Habra, MA, Jimenez, CJ, Subbiah, V, Waguespack, SG, Williams, MD, Zafereo, M, Sherman, SI. Emergence of Resistance-Associated Mutations of RET V804M and KRAS in Medullary Thyroid Carcinoma (MTC) Patients Treated with Tyrosine Kinase Inhibitors (TKI) Cabozantinib and Vandetanib, 2019. e-Pub 2019.
59. Jethanandani A, Kamal M, Cabanillas ME, Mohamed AS, Ferrarotto R, Zafereo M, Garden AS, Morrison WH, Skinner HD, Frank SJ, Phan J, Reddy J, Rosenthal DI, Fuller CD, Gunn GB. Local Regional Patterns of Failure Following Postoperative IMRT for Anaplastic Thyroid Cancer 102(3):e227-e228, 2018. e-Pub 2018.
60. Dadu R, Cabanillas ME, de Groot P, Chang JY, Tang C, Sherman SI, Busaidy NL, Waguespack SG, Hu MI, Ying A, Habra M, Menon H, Welsh J. Ipilimumab with stereotactic ablative radiation therapy (SABR): Results of a thyroid cancer expansion cohort, 2018. e-Pub 2018.
61. Qin Y, Wang JR, Iyer P, Cote G, Busaidy N, Dadu R, Zafereo M, Williams M, Ferrarotto R, Gunn B, Cabanillas ME. Clinical utility of plasma cell-free DNA in anaplastic thyroid cancer, 2018. e-Pub 2018.
62. Simmons G, Nguyen H, Kaya D, Ahmed S, Dadu R, Cabanillas M, Waguespack S, Shah K. Imaging findings of Cancer Immunotherapy Induced Hypophysitis, an Update, 2018. e-Pub 2018.
63. Wang JR, Cote GJ, Zafereo M, Iyer PC, Dadu R, Busaidy NL, Gross ND, Sturgis EM, Ferrarotto R, Lu C, Gunn GB, Myers J, Lai SY, Williams MD, Cabanillas ME. Facilitating rapid precision oncology in anaplastic thyroid cancer: Clinical implications of next generation sequencing (NGS) mutation testing and impact on survival suppl; abstr 6023, 2018. e-Pub 2018.
64. Drilon AE, Subbiah V, Oxnard GR, Bauer TM, Velcheti V, Lakhani NJ, Besse B, Park K, Patel JD, Cabanillas ME, Johnson ML, Reckamp KL, Boni V, Loong HHF, Schlumberger M, Solomon B, Cruickshank S, Rothenberg SM, Shah MH, Wirth LJ. A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers suppl; abstr 102, 2018. e-Pub 2018.
65. Oxnard GR, Drilon AE, Shah MH, Wirth LJ, Bauer TM, Velcheti V, Lakhani NJ, Besse B, Park K, Patel JD, Cabanillas ME, Sherman EJ, Gordon K, Smith S, Nguyen M, Zhu E, Rothenberg SM, Ebata K, Tuch BB, Subbiah V. Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292 suppl; abstr 9048, 2018. e-Pub 2018.
66. Keam B, Kreitman RJ, Wainberg ZA, Cabanillas ME, Cho DC, Italiano A, Stein A, Cho J, Schellens JHM, Wen PY, Zielinski CC, Boran A, Mookerjee B, Burgess P, Rangwala F, Subbiah V. Updated efficacy and safety data of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated anaplastic thyroid cancer (ATC), 2018. e-Pub 2018.
67. Wang JR, Zafereo ME, Dadu R, Ferrarotto R, Busaidy NL, Lu C, Ahmed S, Williams MD, Sturgis EM, Goepfert RP, Gross ND, Lai SY, Gunn GB, Phan J, Rosenthal D, Fuller D, Morrison W, Iyer P, Cabanillas ME. Neoadjuvant targeted therapy followed by surgical resection in BRAFV600E-mutated anaplastic thyroid carcinoma, 2018. e-Pub 2018.
68. Velcheti V, Bauer T, Subbiah V, Cabanillas ME, Lakhani N, Wirth L, Oxnard J, Shah M, Sherman EJ, Smith S, Eary T, Cruickshank S, Tuch B, Ebata K, Nguyen M, Corsi-Travali S, Rothenberg SM, Drilon A. LOXO-292, a potent, highly selective RET inhibitor, in MKI-resistant RET fusion-positive lung cancer patients with and without brain metastases. The IASLC 18th World Conference on Lung Cancer (WCLC), Japan, 2017. e-Pub 2017.
69. Iyer P, Ferrarotto R, Gule-Monroe M, Busaidy N, Dadu R, Habra M, Williams MD, Hofmann M, Zafereo M, Skinner H, Cabanillas ME. Pembrolizumab added to Kinase Inhibitor (KI) therapy in Anaplastic Thyroid Carcinoma (ATC): A Single Cancer Center’s Experience. Thyroid, 87th Annual Meeting of the American Thyroid Association (ATA) 27(1), 2017. e-Pub 2017.
70. Busaidy N, Cabanillas ME, Sherman S, Habra MA, Dadu R, Hu MI, Jimenez C, Waguespack SG, Subbiah V, Ying AK, Gagel RF, Cote G. Emergence of V804M resistance gatekeeper mutation in sporadic medullary thyroid carcinoma patients treated with TKI tyrosine kinase inhibitors. Thyroid, 87th Annual Meeting of the American Thyroid Association (ATA) (oral presentation) 27(1), 2017. e-Pub 2017.
71. Iyer P, Cote GJ, Dadu R, Busaidy N, Ferrarotto R, Hess KR, Gule-Monroe M, Subbiah V, Hofmann M, Gross ND, Zafereo M, Cabanillas ME. Circulating BRAFV600E cell-free DNA (cfDNA) detected by droplet digital PCR (ddPCR) as a biomarker for monitoring response to therapy in the management of BRAF mutated (BRAFm) anaplastic thyroid carcinoma (ATC) patients (pts). Thyroid, 87th Annual Meeting of the American Thyroid Association (ATA) 27(1), 2017. e-Pub 2017.
72. Williams MD, Cabanillas ME, Zafereo M, Cote GJ, Liu B. Altered Metalloproteinases in Aggressive Hurthle Cell Carcinomas. Thyroid 27(1), 2017. e-Pub 2017.
73. Kazzaz F, Cabanillas ME, Faiz S. Lenvatinib Associated Bilateral Spontaneous Pneumothoraces. Thyroid 27(1), 2017. e-Pub 2017.
74. Danysh BP, Busaidy NL, Sinha D, Evans KW, Akcakanat A, Meric-Bernstam F, Cabanillas ME, Ringel MD, Shah MH, Hofmann M. BRAF Mutant Papillary Thyroid Cells with Concurrent Mutations Along the KRAS-RAC1 Axis Develop Resistance to BRAF(V600E)-Inhibitors and are Associated with Increases in EMT Markers. Thyroid 27(1), 2017. e-Pub 2017.
75. Iyer P, Cote GJ, Dadu R, Ferrarotto R, Busaidy NL, Hofmann M, Zafereo M, Williams MD, Subbiah V, Cabanillas ME. Circulating BRAF V600E Cell-Free DNA Detected by Droplet Digital PCR (DDPCR) as a Biomarker in the Management of Anaplastic Thyroid Carcinoma (ATC) Patients. Thyroid 27(1), 2017. e-Pub 2017.
76. Puli O, Danysh BP, Sinha D, Cote GJ, Cabanillas ME, Hofmann M. ETV5, An ETS Family Transcription Factor, Drives Epithelial-To Mesenchymal Transition Through Expression of Twist 1 in Papillary Thyroid Cancer. American Thyroid Association 27(1), 2017. e-Pub 2017.
77. Iyer P, Cote GJ, Dadu R, Busaidy NL, Ferrarotto R, Hess K, Gule-Monroe M, Subbiah V, Hofmann MC, Gross N, Zafereo M, Williams MD, Subbiah V, Cabanillas ME. Circulating BRAFV600E cell-free DNA detected by droplet digital PCR (ddPCR) as a biomarker for monitoring response to therapy in the management of anaplastic thyroid carcinoma (ATC) patients. 87th Annual Meeting of the American Thyroid Association (ATA) in Victoria, British Columbia, Canada (short call abstract), 2017. e-Pub 2017.
78. Danysh BP, Busaidy NL, Sinha DK, Evans KW, Moss TJ, Akcakanat A, Ringel MD, Cabanillas ME, Hofmann MC. BRAF Mutant PTC Cells with Concurrent Mutations Along the KRAS-RAC1 Axis Develop Resistance to BRAF(V600E)-Inhibitors and Are Associated with Increases in EMT Markers, 2017. e-Pub 2017.
79. Ho A, Chau N, Wong D, Cabanillas ME, Bauman J, Brose MS, Bible K, Boni V, Brana I, Ferte C, Even C, Burrows F, Kessler L, Mishra V, Magnuson K, Scholz C, Gualberto A. Preliminary results from a phase 2 proof of concept trial of tipifarnib in tumors with HRAS mutations, 2017. e-Pub 2017.
80. Welsh JW, Tang C, de Groot P, Naing A, Raju U, Shaaban S, Chang SY, Cushman T, Heymach J, Dadu R, Cabanillas ME, Hess K, Massarelli E, Subbiah V, Fu S, Papadimitrakopoulou V, Gomez DR, Hahn SM, Komaki RU, Hong D. Phase II 5-arm trial of ipilimumab plus lung or liver stereotactic radiation for patients with advanced malignancies. ASTRO's 59th Annual Meeting, 2017. e-Pub 2017.
81. Jaber T, Denái M, Grubbs E, Trotter C, Zafereo M, Cabanillas ME, Dadu R, Cote G, Hu M. The Utility of the Calcitonin (Ctn) to Carcinoembryogenic Antigen (CEA) Ratio in Prognostication of Medullary Thyroid Carcinoma (MTC). 3rd World Congress on Thyroid Cancer, 2017. e-Pub 2017.
82. Konda B, Knopp MV, Martin PR, Geyer S, Cabanillas ME, De Souza JA, Wirth LJ, Menefee ME, Liu SV, Shah MH. Effect of cabozantinib on bone turn over markers (BTM) and bone metastases (bm) in radioactive iodine (RAI) refractory differentiated thyroid cancer (DTC). J Clin Oncol 35:suppl; abstr e17580, 2017. e-Pub 2017.
83. Ho AL, Chau NC, Wong DJL, Cabanillas ME, Bauman JR, Bible KC, Brose MS, Calvo E, Boni V, Burrows F, Melvin CL, Scholz CR, Gualberto A. An open-label, phase II study of tipifarnib for the treatment of HRAS mutant solid tumors, including squamous cell carcinomas of the head and neck. J Clin Oncol 35:suppl; abstr TPS2618, 2017. e-Pub 2017.
84. Kutahyalioglu M, Kwatampora LJ, Korivi BR, Ibrahim EY, Shouhao Zhou S, Cabanillas ME, Jimenez C, Dadu R, Habra MA, Fogelman D, Busaidy NL. The Effects of Kinase Inhibitors on Body Composition in Endocrine Tumor Patients- Pilot Study. 99th Annual Meeting of the Endocrine Society, 2017. e-Pub 2017.
85. Jaber T, Waguespack SG, Cabanillas ME, Vu T, Santos EB, Dadu R, Busaidy NL. Efficacy of Targeted Therapy in Resensitization to Radioactive Iodine (RAI) in Advanced Thyroid Cancer: The MD Anderson Experience. 99th Annual Meeting of the Endocrine Society (oral presentation), 2017. e-Pub 2017.
86. Ho A, Chau N, Wong D, Cabanillas M, Mehra R, Bible K, Brose M, Boni V, Burrows F, Melvin C, Scholz C, Gualberto A. Preliminary evidence of clinical activity with tipifarnib by targeting HRAS mutations in squamous cell carcinomas of the head and neck (oral presentation). Targeted Anticancer Therapies, Paris, France, 2017. e-Pub 2017.
87. Smith A, Williams MD, Cabanillas ME, Stewart J, Wang W, Krishnamurthy S, Roy-Chowdhuri S. Utility of BRAF V600E Immunoperoxidase Stain in Cytology Preparations of Cell Block and Aspirate Smears in Thyroid Cancers. 106th Annual Meeting of United States & Canadian Academy of Pathology, 2017. e-Pub 2017.
88. Bhosale PR, Gardner CS, Wei W, Qayyum A, Cabanillas ME. CT as a biomarker for assessing response in medullary thyroid cancer patients on targeted therapy with carbozantinib. Radiological Society of North America (RSNA), 2016. e-Pub 2016.
89. Dadu R, Vilalabos PA, Para Cuentas ER, Rodriguez Canales J, Wistuba II, Zhou S, Williams M, Cabanillas M. Anaplastic Thyroid Cancer (ATC) is a Hot Immunogenic Environment: Immunoprofiling of a Large Cohort of ATC Tumors. Thyroid (oral abstract #12) 26, 2016. e-Pub 2016.
90. Voss RK, Feng L, Lee JE, Perrier ND, Graham PH, Hyde SM, Cabanillas ME, Cote GJ, Gagel RF, Grubbs EG. Medullary Thyroid Carcinoma in MEN2A: ATA Risk Level does not Predict Disease Aggressiveness. American Thyroid Association, 2016. e-Pub 2016.
91. Iyer P, Dadu R, Busaidy NL, Ferrarotto R, Gule-Monroe MK, Lu C, Williams MD, Cabanillas ME. Harvesting high-hanging fruit: Targeted Therapy for BRAF mutant (BRAFm) and BRAF wild-type (BRAFwt) Anaplastic Thyroid Cancer (ATC) patients. American Thyroid Association, 2016. e-Pub 2016.
92. Iyer P, Cabanillas ME, Waguespack S, Naifa NL, Hu M, Dadu R. Immunotherapy-related destructive thyroiditis: A Cancer Center Experience. American Thyroid Association, 2016. e-Pub 2016.
93. Pena I, Clayman G, Grubbs EG, Bergeron Jr JM, Waguespack SG, Cabanillas ME, Dadu R, Fellman BM, Li Y, Hu MI, Sturgis EM, Zafereo ME. Management of the Lateral Neck Compartment in Patients with Sporadic Medullary Thyroid Cancer. 9th International American Head and Neck Society Meeting, 2016. e-Pub 2016.
94. Thuro BA, Cabanillas ME, Busaidy NL, Dadu R, Jimenez C, Graham PH, Esmaeli B. Thyroid-related Eye Disease in Cancer Patients. International Thyroid Eye Disease Symposium Program, 2016. e-Pub 2016.
95. Sandulache V, Williams MD, Lai SY, Lu C, William WN, Busaidy NL, Cabanillas ME. Clinical genomic testing of anaplastic thyroid carcinoma (ATC) and need for integration into future prospective clinical trials. Journal of Clinical Oncology 34, 2016. e-Pub 2016.
96. Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou MA, Karp DD, Gomez DR, Komaki R, Sharma P, Naing A, Hong DS. Phase I trial combining ipilimumab + high dose stereotactic radiation: Results and serum immune correlates. J Clin Oncol 34:suppl; abstr 3022, 2016. e-Pub 2016.
97. Xu JY, Handy BC, Waguespack SG, Hu MI, Busaidy NL, Jimenez C, Cabanillas ME, Cote GJ, Sherman SI. Effect of circulating tumor cells (CTCs) on overall survival in metastatic medullary thyroid cancer (metMTC). J Clin Oncol 34:suppl; abstr e17547, 2016. e-Pub 2016.
98. Xu JY, Zaidi TM, Cote GJ, Hu MI, Waguespack SG, Cabanillas ME, Ying AK, Busaidy NL, Habra MA, Shanbhag N, Truong D, Yu RK, Shete S, Katz RL, Sherman SI. Accurate detection of circulating tumor cells (CTCs) in patients with metastatic papillary thyroid cancer (MPTC) via an interphase fluorescence in situ hybridization (IFISH) assay. J Clin Oncol 34:suppl; abstr e17550, 2016. e-Pub 2016.
99. Khan SA, Ci B, Gerber DE, McFadden DG, Beg MS, Xie Y, Kurian P, Cabanillas ME, Busaidy NL, Sherman SI, Heilmann A, Ross JS, Bailey M, Burtness B, Ali SM. Comprehensive genomic sequencing (CGS) of 90 patient samples of anaplastic thyroid cancer (ATC). J Clin Oncol 34:suppl; abstr 6014, 2016. e-Pub 2016.
100. Ahmed S, Ghazarian M, Cabanillas ME, Vu T, Debnam J. Imaging of Anaplastic Thyroid Carcinoma. 116th American Roentgen Ray Society (ARRS) Annual Meeting (oral presentation), 2016. e-Pub 2016.
101. Rao S, Dadu R, Busaidy N, Lai S, Gunn B, Lu C, William W, Cabanillas ME. Patterns of failure in Anaplastic Thyroid Cancer (ATC) patients. The Endocrine Society's 98th Annual Meeting, 2016. e-Pub 2016.
102. Cabanillas ME, Gunn G, Williams M, Busaidy N, Jr WW, Lu C, Lai S. Facilitating Anaplastic Specialized Treatments (FAST)—a Multidisciplinary Anaplastic Thyroid Cancer (ATC) Team. 2016 Multidisciplinary Head and Neck Cancer Symposium, 2016. e-Pub 2016.
103. Shah MH, De Souza J, Wirth L, Menefee ME, Liu S, Geyer S, Wright J, Villalona M, Cabanillas ME. Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy: Results of NCI- and ITOG-sponsored Multicenter Phase II Clinical Trial. 15th International Thryroid Congress (oral presentation), 2015. e-Pub 2015.
104. Dadu R, Rodriguez Canales J, Wistuba II Tian W, Liu H, Grubbs EG, Cote G, Ray G, Williams M, Cabanillas ME. Immune markers in medullary thyroid cancer (MTC) and their clinical significance. 15th International Thyroid Congress, (oral presentation), 2015. e-Pub 2015.
105. Stewart AA, Williams MD, Hu MI, Feng L, Lee JE, Perrier ND, Cabanillas ME, Cote GH, Grubbs EG. The role of somatic RET and RAS mutations in predicting outcomes in sporadic medullary thyroid carcinoma. 36th Annual Meeting of the American Association of Endocrine Surgeons, 2015. e-Pub 2015.
106. Shah K, Ahmed S, Cabanillas M, Pitteloud M, Waguespack S, Dadu R. Imaging Findings of Cancer Immunotherapy Induced Hypophysitis. 53rd Annual Meeting of the American Society of Neuroradiology (oral presentation), 2015. e-Pub 2015.
107. Weitzman S, Peicher K, Dadu R, Hu MI, Jimenez C, Gardner C, Qayyum A, Hernandez M, Cabanillas ME. Salvage Therapy: When a Tyrosine Kinase Inhibitor (TKI) Fails in Advanced Medullary Thyroid Cancer (MTC). 97th Annual Meeting of the Endocrine Society (oral presentation), 2015. e-Pub 2015.
108. Kwatampora L, Cabanillas ME, Korivi BR, Fogelman D, Dadu R, Busaidy N. Effect of Cabozantinib on Body Composition in Advanced Thyroid Cancer. 97th Annual Meeting of the Endocrine Society, 2015. e-Pub 2015.
109. Patham B, Bible KC, Waguespack SG, Cabanillas ME. Anaplastic Transformation (ATC-t) of Papillary Thyroid Cancer (PTC) after Treatment with BRAF Inhibitors (BRAFi). 97th Annual Meeting of the Endocrine Society, 2015. e-Pub 2015.
110. Pitteloud MJ, Dadu R, Cabanillas ME, Shah K, Hu MI, Habra MA, Waguespack SG. Hypophysitis in the Age of Cancer Immunotherapy: Experience in a Large Cancer Center. 97th Annual Meeting of the Endocrine Society (oral presenation), 2015. e-Pub 2015.
111. Chen H, Luthra R, Routbort M, Patel KP, Singh R, Dang H, Barkoh BA, Cabanillas M, Aldape K, Broaddus R, Williams MD. Mutation Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: The MDACC experience. 2015 United States & Canadian Academy of Pathology Annual Meeting, 2015. e-Pub 2015.
112. Farhood Z, Trotter C, Hu M, Cabanillas ME, Jackson M, Rich T, Lee J, Perrier N, Grubbs E. Assessing the accuracy of self-reported medical history amongst the MEN2 population. 10th Annual Meeting of the Association of Academic Surgeons (oral presenation), 2015. e-Pub 2015.
113. Weitzman S, Waguespack SG, Ying AK, Hu MI, Cabanillas ME. Pain may represent treatment response to targeted therapy in patients with thyroid cancer. 15th International Thyroid Congress, 2015. e-Pub 2015.
114. Pezzi TA, Sandulache VC, Pezzi CM, Turkeltaub AE, Feng L, Cabanillas ME, Williams MD, Lai S. Treatment and Survival of Patients with Insular Thyroid Carcinoma: 508 Cases from the National Cancer Data Base. 15th International Thyroid Congress, 2015. e-Pub 2015.
115. Cabanillas ME, Dadu R, Waguespack SG. Response to dabrafenib and trametinib in a patient BRAF V600E-mutated (BRAFm) Anaplastic Thyroid Cancer (ATC). 15th International Thyroid Congress, 2015. e-Pub 2015.
116. Cabanillas ME, Williams MD, Gunn B, Weitzman SP, Burke L, Busaidy N, Ying A, William WN, Lu C, Lai S. Facilitating Anaplastic Thyroid Cancer Specialized Treatment (FAST): A model for increasing enrollment to Anaplastic Thyroid Cancer (ATC) clinical trials. 15th International Thyroid Congress, 2015. e-Pub 2015.
117. Cabanillas ME, Waguespack SG, Pitteloud M, Roman-Gonzalez A, Jessop A, Santos E, Davies M, Dadu R. Anti-CTLA4-induced Graves Disease (GD): A rare cause of hyperthyroidism (hyperT) in patients (pts) with metastatic melanoma (mM). 15th International Thyroid Congress, 2015. e-Pub 2015.
118. Dadu R, Rodriguez J, Tian W, Liu H, Williams M, Wistuba I, Cabanillas ME. Targeting immune system in anaplastic thyroid cancer (ATC): a potential treatment approach. 15th International Thyroid Congress (oral presentation), 2015. e-Pub 2015.
119. Sakamuri D, Betancourt Cuellar SL, Glitza IC, Fu S, Wheler JJ, Falchook GS, Tsimberidou AM, Hong DS, Subbiah V, Fanale MA, Cabanillas ME, Meric-Bernstam F, Janku F. Phase 1 study of ipilimumab (anti CTLA-4) in combination with lenalidomide in patients with advanced cancers. American Association of Cancer Research (AACR), 2015. e-Pub 2015.
120. Kutahyalioglu M, Elsayes KM, Vicens RA, Sircar K, Jazaerly T, Ozsari L, Jimenez C, Waguespack SG, Busaidy NL, Cabanillas ME, Grubbs E, Habra MA. Preexisting Adrenal Masses in Patients with Adrenocortical Carcinoma: Beyond Size Alone. 16th International Congress of Endocrinology & 96th Annual Meeting of the Endocrine Society, 2014. e-Pub 2014.
121. Busaidy NL, Cabanillas ME, Dadu R, Jimenez C, Habra, Vaporciyan A, Morris L, Perrier ND, Hoff, AO. Metastatic Parathyroid Carcinoma and Hypercalcemia Responds to Treatment with Sorafenib. 16th International Congress of Endocrinology & 96th Annual Meeting of the Endocrine Society, 2014. e-Pub 2014.
122. Dadu RD, Shah K, Bassett, RL, Busaidy NL, Waguespack SG, Sherman SI, Habra MA, Jimenez CJ, Hu MI, Ying AK, Cabanillas ME. Is There an Alternative Treatment Option for Patients with Advanced Papillary Thyroid Cancer (PTC) Harboring the BRAFV600E Mutation?. e-Pub 2014.
123. Cabanillas ME, Dadu RD, Sturgis E. Neoadjuvant vemurafenib for locally advanced papillary thyroid cancer harboring BRAF V600E mutation: a case report. e-Pub 2014.
124. Dadu R, Hu MI, Cleeland C, Busaidy NL, Habra M, Waguespack SG, Sherman SI, Ying A, Fox P, Cabanillas ME. The efficacy of the natural clay, CASAD, in reducing medullary thyroid cancer (MTC)-related diarrhea and its effects on quality of life (QOL): a pilot study. 84th Annual Meeting of the American Thyroid Association, 2014. e-Pub 2014.
125. Brose MS, Cabanillas ME, Cohen EE, Wirth L, Sherman SI, Riehl T, Yue H, Sherman E. An Open-Label, Multi-center Phase 2 Study of the BRAF Inhibitor Vemurafenib in Patients With Metastatic or Unresectable Papillary Thyroid Cancer (PTC) Positive for the BRAF V600 Mutation and Resistant to Radioactive Iodine. The European Cancer Congress 2013 (oral presentation), 2013. e-Pub 2013.
126. Sherman SI, Michaelis C, Gornet TG, Handy BC, Waguespack SG, Hu MI, Busaidy N, Jimenez C, Cabanillas ME, Cote G. Overall Survival is Reduced in Patients with Detectable Circulating Tumor Cells from Metastatic Medullary Thyroid Cancer. 83rd Annual Meeting of the American Thyroid Association, 2013. e-Pub 2013.
127. Danysh BP, Cabanillas ME, Hofmann MC. Effects of Activated Estrogen Receptors on Acquired BRAF Inhibitor Resistance in Papillary Thyroid Cancer (PTC). 83rd Annual Meeting of the American Thyroid Association, 2013. e-Pub 2013.
128. Sherman E, Cohen EW, Cabanillas ME, Gianoukakis A, Chuan Tai Y, Langland R, Brose MS. Detection of BRAFV600E in Cell Free DNA from Patients with Papillary Thyroid Cancer. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2013. e-Pub 2013.
129. Dadu R, Devine C, Hernandez M, Busaidy N, Waguespack SG, Hu MI, Ying A, Habra MA, Jimenez C, Sellin RV, Cote G, Sherman S, Cabanillas ME. Survival and Efficacy of Salvage Tyrosine Kinase Inhibitors (TKIs) after first line Sorafenib (SOR) Failure in Patients with Advanced Differentiated Thyroid Cancer (DTC). 83rd Annual Meeting of the American Thyroid Association (Oral Presentation), 2013. e-Pub 2013.
130. Adili A, Chasen B, Dadu R, Williams M, Ali SK, Waguespack SG, Habra MA, Cote G, Busaidy N, Jimenez C, Hu MI, Sellin RV, Sherman SI, Cabanillas ME. Outcomes of Patients with Poorly Differentiated Thyroid Cancer of Follicular Origin Treated With First Line Sorafenib. 83rd Annual Meeting of the American Thyroid Association (Oral Presentation), 2013. e-Pub 2013.
131. Dadu R, Waguespack SG, Cabanillas ME. Indeterminate thyroid nodules on cytology: Should presence of RAS mutation change management?. 95th Annual Meeting of the Endocrine Society, 2013. e-Pub 2013.
132. Cabanillas ME, Holsinger FC, Sturgis EM, Habra MA, Davies MA, Munsell M, French J, Busaidy N, Hu MI, Sherman SI. Pharmacodynamics study of neoadjuvant vemurafenib (VEM) in patients (pts) with BRAF mutated, locally advanced papillary thyroid cancer (PTC): Trials in Progress Session. J Clin Oncol, 2013. e-Pub 2013.
133. Ali SK, Dadu R, Lu C, Grubbs E, Blevins D, Cabanillas ME. Peculiar Presentation of Papillary Thyroid Cancer. 95th Annual Meeting of the Endocrine Society, 2013. e-Pub 2013.
134. Dadu R, Devine C, Hernandez M, Busaidy N, Waguespack S, Ying A, Habra M, Thosani S, Hu M, Cabanillas ME. Is 2nd line targeted therapy beneficial in patients with differentiated thyroid cancer after 1st line sorafenib failure?. J Clin Oncol 31, 2013. e-Pub 2013.
135. Dadu R, Shah K, Waguespack S, Sherman SI, Habra M, Busaidy N, Jimenez C, Ying A, Hu M, Cabanillas ME. Efficacy and tolerability of vemurafenib in BRAFV600E positive papillary thyroid cancer. 83rd Annual Meeting of the American Thyroid Association, 2013. e-Pub 2013.
136. Dadu R, Hu M, Habra M, Waguespack S, Ying A, Busaidy N, Cabanillas M. Salvage Therapy with tyrosine kinase inhibitors for differentiated thyroid carcinoma after first line sorafenib failure. 95th Annual Meeting of the Endocrine Society, 2013. e-Pub 2013.
137. Dadu R, Busaidy N, Habra M, Hu M, Jimenez C, Ying A, Waguespack S, Cabanillas ME. Off label use of sorafenib in patients with differentiated thyroid cancer: Focus on tolerability profile. Texas Chapter of the American Association of Clinical Endocrinologists, 2013. e-Pub 2013.
138. Dadu R, Lu C, Piha-Paul S, Cote G, Cabanillas ME. Dual Somatic Mutations in BRAF V600E and PIK3CA (PI3K) in Patients with Aggressive Papillary Thyroid Cancer (PTC). 82nd Annual Meeting of the American Thyroid Association, 2012. e-Pub 2012.
139. Thosani SN, Busaidy N, Cabanillas M, Cote G, Grubbs E, Habra M, Hu M, Perrier N, Ayala-Ramirez M, Rich T, Waguespack SG, Ying A, Jimenez C. Characterization of Pheochromocytomas in MEN 2 with RET codon 918 and 634 mutations. 94th Annual Meeting of the Endocrine Society, 2012. e-Pub 2012.
140. Busaidy NL, Megahed NN, Cabanillas ME, Hale KS, Jimenez C, Habra HA, Kupferman M, Grubbs E, Mills G, Williams MD. Molecular Profiling of Advanced Thyroid Carcinomas. 94th Annual Meeting of the Endocrine Society, 2012. e-Pub 2012.
141. Schlumberger M, Jarzab B, Cabanillas ME, Robinson B, Pacini F, Ball DW, McCaffrey JC, Newbold K, Allison R, Martins R, Licitra LF, Shah MH, Bodenner D, Elisei R, Burmeister LA, Funahashi Y, Sellecchia R, Andersen C, O'Brien JP, Sherman SI. A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC). J Clin Oncol suppl; abstr 5591, 2012. e-Pub 2012.
142. Ball DW, Sherman SI, Jarzab B, Cabanillas ME, Martins R, Shah MH, Bodenner D, Newbold K, Licitra LF, Topliss D, Allison R, Kadowaki T, Funahashi Y, Matijevic M, Sachdev P, O'Brien JP, Schlumberger M. Lenvatinib treatment of advanced RAI-refractory differentiated thyroid cancer (DTC): Cytokine and angiogenic factor (CAF) profiling in combination with tumor genetic analysis to identify markers associated with response. J Clin Oncol suppl; abstr 5518, 2012. e-Pub 2012.
143. Cabanillas ME, Brose MS, Ramies DA, Lee Y, Miles D, Sherman SI. Antitumor activity of cabozantinib (XL184) in a cohort of patients (pts) with differentiated thyroid cancer (DTC). J Clin Oncol suppl; abstr 5547, 2012. e-Pub 2012.
144. Cabanillas ME, Brose MS, Ramies DA, Lee Y, Miles D, Sherman SI. Anti-tumor Activity Observed in a Cohort of Patients (pts) with Differentiated Thyroid Cancer (DTC) in a Phase 1 Study of Cabozantinib (XL184). American Thyroid Association, 81st Annual Meeting, 2011. e-Pub 2011.
145. Sherman SI, Jarzab B, Cabanillas ME, Licitra LF, Pacini F, Martins R, Robinson B, Ball D, McCaffrey J, Shah MH, Bodenner D, Allison R, Newbold K, Elisei R, O'Brien JP, Schlumberger M. Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology. J Clin Oncol 29, 2011. e-Pub 2011.
146. Choueiri TK, Pal SK, Cabanillas ME, Ramies DA, Tseng L, Holland JS, Morrissey S, Dutcher JP. Antitumor activity observed in a phase I drug–drug interaction study of cabozantinib (XL184) and rosiglitazone in patients (pts) with renal cell carcinoma (RCC) and differentiated thyroid cancer (DTC). J Clin Oncol 29, 2011. e-Pub 2011.
147. Ejaz S, Waguespack SG, Sellin RV, Busaidy NL, Jimenez C, Ying AK, Hu MI, Cabanillas ME, Gagel RF, Habra MA. ACTH-Dependent Ectopic Cusing's Syndrome: The University of Texas MD Anderson Cancer Center Experience. Endocrine Reviews (92nd Annual Meeting of the Endocrine Society) 31(3):S2365, 2010. e-Pub 2010.
148. Michaelis CL, Cote GJ, Santarpia L, Klein MJ, Gornet TG, Fritsche HA, Busaidy NL, Waguespack SG, Cabanillas ME, Hu MI, Jimenez C, Sherman SI. Detection of Circulating Tumor Cells (CTCs) in Patients with Thyroid Cancer. Endocrine Reviews (92nd Annual Meeting of the Endocrine Society) 31(3):S615, 2010. e-Pub 2010.
149. Cabanillas ME, Kurzrock R, Sherman SI, Tsimberidou AM, Waguespack S, Naing A, Busaidy NL, Gagel R, Wright JJ, Hong DS. Phase I trial of combination sorafenib and tipifarnib: The experience in advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC). J Clin Oncol 28(15s):(suppl; abstr 5586), 2010. e-Pub 2010.
150. Hightower E, Devin J, Fuller G, Corley L, McCutcheon IE, Waguespack SG, Shah K, Hess K, Cabanillas ME. Phospho-histone H3 (PHH3) Immunoreactivity in Non-Functioning Pituitary Adenomas. Endocrine Reviews (92nd Annual Meeting of the Endocrine Society) 31(3):S340, 2010. e-Pub 2010.
151. Cabanillas ME, David H, Waguespack S, Sherman SI, Hernandez M, Hu M, Habra M, Busaidy N. Stable disease is an important endpoint in patients with progressive, differentiated thyroid cancer treated with sorafenib. 80th Annual Meeting of the American Thyroid Association 19(S1):S1-S93, 2009. e-Pub 2009.
152. Cabanillas ME, Jehaimi CT, Waguespack SG. Primary Pigmented Nodular Adrenocortical disease (PPNAD) in a Patient with Carney Complex (CC). 16th Annual Meeting American Association of Clinical Endocrinologists, 2009. e-Pub 2009.
153. Cabanillas ME, Waguespack SG, Bronstein Y, Williams M, Feng L, Sherman SI, Busaidy NL. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: The M. D. Anderson Cancer Center experience. J Clin Oncol 27(15s):abstract 6060, 2009. e-Pub 2009.
154. Cabanillas ME, Thomas DA, Kantarjian H, Mattiuzzi GN, Bekele BN, Foudray MC, Cassat JL, Cortes JE. Epoetin-alpha compared to standard of care decreases number of packed red blood cell transfusions in patients receiving hyper-CVAD for acute lymphocytic leukemia, lymphoblastic lymphoma, and Burkitt's lymphoma. J Clin Oncol 18S, 2007. e-Pub 2007.
155. Cabanillas ME. Spectrum of Hormone Abnormalities Contributing to Bone Loss in Adult Patients with Acute Lymphocytic Leukemia (ALL) and Lymphoblastic Lymphoma (LL). 28th Annual Meeting of the American Society of Bone and Mineral Research, 2006. e-Pub 2006.
156. Mattiuzzi GN, Cortes JE, Faderl S, Cabanillas ME, Giles FJ, O’Brien S, Garcia-Manero G, Kantarjian H. Patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome (HR-MDS) treated with targeted therapy may benefit from prophylactic measures against infections. Blood 11(197b):abstract 4483, 2006. e-Pub 2006.
157. Vu KD, Thomas DA, Hubbard JC, Faderl S, Cortes J, Cabanillas ME, Garcia-Manero G, O’Brien SM, Kantarjian H. Incidence of venothromboembolism (VTE) in patients with acute lymphocytic leukemia, Burkitt’s leukemia/lymphoma or lymphoblastic leukemia. Blood 11:213b, abstract 4534, 2006. e-Pub 2006.
158. Cabanillas ME, Thomas DA, Hoff G, Mattiuzzi G, Foudray MC, Kantarjian H, Escalante CP, Gagel RF. Vitamin D (VD) Deficiency and Skeletal Abnormalities are Very Common Findings in Adult Acute Lymphocytic Leukemia (ALL) and Lymphoblastic Lymphoma (LL). J Clin Oncol 23:16s, Abstract 6608, 2005. e-Pub 2005.
159. Cabanillas ME, Mattiuzzi G, Thomas D, Vu K, Ossa G, Garcia-Manero G, Cortes J, Giles F, O’Brien S, Kantarjian H. Invasive fungal infections (IFI) in patients (pts) receiving hyper-CVAD. J Clin Oncol 23:12s, abstract 6727, 2004. e-Pub 2004.
160. Weiser MA, Cabanillas ME, Konopleva M, Thomas DA, Pierce SA, Escalante CP, Kantarjian HM, O’Brien SM. Relationship between remission duration and hyperglycemia during induction treatment of acute lymphocytic leukemia (ALL) with hyperCVAD/MTX-araC regimen. J Clin Oncol 22(588), 2003. e-Pub 2003.
161. Quintas-Cardama A, Ault P, Kantarjian H, O’Brien S, Cabanillas M, Rios MB, Verstovsek S, Talpaz M, Cortes J. Darbepoetin alfa (AranespTM) for anemia during imatinib mesylate (GleevecTM) therapy for chronic phase chronic myeloid leukemia (CML). Blood 102:4970b, 2003. e-Pub 2003.
162. Cabanillas ME, Mattiuzzi GN, Weiser MA, Ossa GZ, Fowler EG, Pierce SA, Kantarjian HM, Garcia-Manero G, Thomas DA. Incidence of invasive fungal infections (IFI) in patients (pts) receiving hyper-CVAD. Blood 102:4688b, 2003. e-Pub 2003.
163. Cabanillas ME, Thomas DA, Cortes J, Faderl S, O’Brien S, Beran M, Younes A, Fayad L, Koller C, Kantarjian H. Outcome with hyper-CVAD and rituximab in Burkitt (BL) and Burkitt-like (BLL) leukemia/lymphoma. J Clin Oncol 22:574, abstract 2309, 2003. e-Pub 2003.
164. Solomon BJ, Drilon A, Wirth LJ, Szpurka AM, Massey AC, Rao X, Barker SS, Wright J, Won H, Cabanillas ME. Mechanisms of Resistance to Selpercatinib in RET Activated NSCLC and MTC from the LIBRETTO-001 Trial.
165. Brose MS, Cabanillas ME, Lin JJ, McDermott RS, Almubarak M, Bauman JR, Casanova M, Kummar S, Lee S, Rieke DT, Oh D, Qi C, Neu N, Burcoveanu D, Mussi CE, Drilon AE, Hong DS, Waguespack SG. Efficacy and safety of larotrectinib in patients with TRK fusion thyroid carcinoma: An updated analysis. ASCO Annual Meeting.
166. Chaudhri AN, Cabanillas ME, Dadu R, Busaidy NL, Cote C, Chowdhuri S. Immunohistochemical (IHC) Testing Versus Next Generation Sequencing (NGS) for Identification of BRAF V600E Mutations in Clinical Practice for Anaplastic Thyroid Cancer.
167. Zafereo M, Wang RJ, Busaidy NL, Dadu R, Iyer PC, Waguespack SG, Xu L, Maniakas A, Banuchi V, Lai SY, Chinn SB, Geiger JL, Kerrigan KC, Khan SA, Moore EJ, Ryder MM, Scharpf J, Worden FP, Williams MD, Cabanillas ME. Neoadjuvant pembrolizumab in combination with dabrafenib and trametinib (DTP) for BRAF V600E-mutated anaplastic thyroid cancer (BRAFm-ATC): A multicenter phase 2 trial. ASCO Annual Meeting.
168. Danysh B, Busaidy N, Sinha D, et al. An Acquired Novel RAC1 (P34R) Mutation Drives BRAF (V600E)- Inhibitor Resistance in a Papillary Thyroid Carcinoma Patient.
169. Gouda MA, Ahmed J, Nelson BE, Nardo M, Roszik: J, Cabanillas ME, Hu MI, Busaidy NL, Sherman SI, Dadu R, Naing A, Karp DD, Ahnert JR, Hong DS, Elamin YY, Blumenschein GR, Heymach J, Meric-Bemstam F, Subbiah V. Intra patient comparative efficacy of selective RET inhibitors using growth modulation index in patients with RET aberrant cancers. ASCO Annual Meeting.
170. Cabanillas ME, Lin JJ, Brose MS, McDermott RS, Almubarak M, Bauman JR, Casanova M, Kummar S, Lee S, Leyvraz S, Oh D, Shen L, Norenberg R, Bernard-Gauthier V, Mussi CE, Hong DS, Drilon AE, Waguespack SG. Larotrectinib (laro) long-term efficacy and safety in patients (pts) with tropomyosin receptor kinase (TRK) fusion thyroid carcinoma (TC). ASCO Annual Meeting.
171. Cabanillas ME, Lin JJ, Brose MS, McDermott RS, Almubarak M, Bauman JR, Casanova M, Kummar S, Lee S, Leyvraz S, Oh D, Shen L, Neu N, Bernard-Gauthier V, Mussi CE, Hong DS, Drilon AE, Waguespack SG. Long-term efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion thyroid carcinoma (TC). ASCO Annual Meeting.
172. Srour SA, Villaflor VM, Lorch JH, Zafereo ME, Gupta S, Hu MI, Dadu R, Lin AY, Lu Y, Ackatz L, Cushing M, Avecilla S, Scognamiglio T, Jin M, Puc J, Liu G, Du K, Mayer SA, Besien KV, Cabanillas ME. Safety and efficacy of AIClO0 chimeric antigen receptor (CAR) T-cell therapy in patients with advanced thyroid cancers: Results from the phase 1 study. ASCO Annual Meeting.

Book Chapters

1. Iyer, PC, Srour, S, Hofmann, M, Cabanillas, ME. Current Trends in Treatment and New Generation of Trials in Thyroid Cancer, 307-324, 2024.
2. Maniakas A, Zafereo M, Cabanillas ME. Anaplastic Thyroid Cancer: New Horizons and Challenges. In: Endocrinol Metab Clin North Am. 2. Elsevier, 391-401, 2022.
3. Kansara, S, Cabanillas, ME, Zafereo, M. Neoadjuvant Therapy for Anaplastic Thyroid Carcinoma, 81-88, 2021.
4. Kansara S, Cabanillas ME, Zafereo M. Neoadjuvant Therapy for Anaplastic Thyroid Carcinoma. In: Innovations in Modern Endocrine Surgery. Springer, 2021.
5. Cabanillas ME, Wang JR. A Patient with BRAFV600E-mutated Anaplastic Thyroid Cancer with Metastatic Disease. In: Thyroid Cancer: A Case-Based Approach. Springer, 2021.
6. Cabanillas ME, Weitzman SP, Dadu R, Gansler T, Zafereo M. Thyroid Cancer. In: The American Cancer Society's Oncology in Practice: Clinical Management. Wiley-Blackwell, 519-531, 2018.
7. Cabanillas ME, Schweppe RE, Dadu R, Cote G, Beadnell TC, Hofmann MC. Translational research and genomics driven trials in thyroid cancer. In: Practical Management of Thyroid Cancer - A Multidisciplinary Approach. 2nd. Springer, 319-338, 2018.
8. Sherman SI, Cabanillas ME, Lai SY. Neoplasms of the Thyroid. In: Holland - Frei Cancer Medicine. 9th. Wiley, 2017.
9. Abadin SS, Cabanillas ME, Boger MS, Perrier ND. Graves' and Plummer's Diseases: Medical and Surgical Management. In: Textbook of Endocrine Surgery. 3rd, 2014.
10. Cabanillas ME, Fever AR. Fever. In: Medical Care of Cancer Patients, 2009.
11. Mora E, Cabanillas ME, Simmons R. Prevention, diagnosis, and treatment in transplant patients. In: Organ Transplant in Latin America, 1998.

Letters to the Editor

1. Gouda MA, Hu MI, Cabanillas ME, Wu J, Meric-Bernstam F, Subbiah V. Weight Gain in Cancer Patients Treated with Brain Penetrant RET-selective Inhibitors. Ann Oncol 34: 946-948, 2023.
2. Cabanillas ME, Williams MD. Letter to the Editor regarding squamoid pattern of anaplastic thyroid carcinoma, a poorly recognized entity. Head Neck 38: 1290, 2016.